ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES

ACPHS PRESIDENT’S REPORT 3

P R E S I D E N T ’ S R E P O R T

A L B A N Y C O L L E G E O F P H A R M A C Y A N D H E A LT H S C I E N C E S

4 ACPHS PRESIDENT’S REPORT

SHORTLY INTO MY FIRST YEAR AS PRESIDENT OF the College, I had a conversation with Larry Doud, the CEO of Rochester Drug Cooperative. I asked Larry about the qualities he looks for in new graduates. He said, “I want them to be practice ready. They need to hit the ground running and be able to solve practical, everyday problems.”

I have thought a lot since then about what it means to be practice ready and have had numerous conversations with faculty, alumni, and preceptors about this subject.

Educating students to be practice ready is always a challenge for a professional school, particularly one focused on pharmacy and the health sciences. There is always conflict about which new subjects to include and which ones to leave out. That is especially true today when our knowledge of human biology and the very practice of health care are changing at unprecedented rates.

While being practice ready is clearly important, we need to strive for something even better. To enjoy success across an entire career, you must be able to anticipate, and adapt to, the shifting demands of your profession. In other words, you need to go Beyond Practice Ready.

Beyond Practice Ready is the name of our current fundraising campaign, but it is not simply a campaign title or marketing slogan. It is a philosophy that we are integrating across all areas and functions of the College, and the Campaign is one of the ways we are working to support those efforts.

To go beyond practice ready is not so much learning a new set of subjects as it is about developing an attitude. It is about being resourceful, adaptable, inventive, and even a little entrepreneurial.

But how do you teach this attitude? How does someone learn these characteristics? Pharmacy education has always had a strong experiential component and pharmacy practice experiences can be transformative. That is the motivation behind

creating our two student operated pharmacies in medically underserved areas of the Capital Region. The first pharmacy – which opened in March – is located in the Hometown Health Centers clinic in Schenectady. The second pharmacy will open in Albany later this year.

These pharmacies are not traditional community pharmacies. They are linked directly to clinics thereby allowing delivery of a wider range of health care services. Being situated in medically underserved areas provides the added benefit of helping serve our communities while exploring a broader scope of health care practice.

These pharmacies will provide students from across all of our programs with a range of entrepreneurial and health care related learning experiences and opportunities. These may include learning how to run a business, the proper way to conduct point of care testing, or learning to counsel and educate community members – just to name a few.

Regardless of their field of study, the students involved in these pharmacies will gain experience that goes beyond the classroom and will benefit them throughout their lives.

Though we are just now formalizing the rollout of our Beyond Practice Ready initiatives, there has been a long line of individuals from ACPHS who have exemplified this approach. We have selected six of these alumni, faculty, and staff to feature in this magazine to illustrate how the Beyond Practice Ready attitude can pave the way for a lifetime of sustained success.

No one knows what the future holds, but one thing is certain – change is coming. Going Beyond Practice Ready will allow ACPHS graduates to become future leaders of health care.

B E Y O N D

P R A C T I C E R E A D YG R E G D E W E Y, P H . D .

P R E S I D E N T


T H E

A G E N D AS T R A T E G I C


A G E N D A

A STRATEGIC PLAN IS, ABOVE ALL ELSE, A PLAN. Like all plans, it guides one’s thinking, but more often than not, it needs to be adjusted in response to a fluid and dynamic world.

Over the past two years, the ACPHS community has worked together to create a Strategic Agenda derived from our Strategic Plan (which was completed in 2012).

The goal of the Strategic Agenda is not to replace the existing Strategic Plan but rather to articulate the original vision in a context that sets priorities and specific metrics.

Since launching this initiative, we have held two Campus retreats, several town hall meetings, and established focus groups for each of the five imperatives of the Strategic Agenda. This community-wide effort has involved faculty, students, academic administration, and professional staff.

Not surprisingly, some aspects of the Strategic Agenda’s implementation have moved faster than others. As you will read, tangible progress has been made in several key areas while other areas present more complex challenges that are not as easily resolved.

Despite the varying degrees of progress to date, our efforts continue to be guided by one unifying principle – to create the best academic experience possible for ACHPS students.

S T R A T E G I C



O N T H E F O L L O W I N G T W O P A G E S A R E T H E F I V E I N I T I A T I V E S T H A T C O M P R I S E T H E A C P H S

S T R A T E G I C A G E N D A A L O N G W I T H U P D A T E S O N T H E P R O G R E S S T H A T H A S B E E N M A D E I N E A C H A R E A .

1. PHARMD+OBJECTIVE: The expansion of pharmacy schools across the country has resulted in a more competitive landscape, not only for attracting students, but also for our graduates gaining employment. We must explore curricular, pedagogical, and programmatic approaches to enhance the competitiveness of our students in the workplace and to make our program stand out from others. In short, we need to define the “+” in PharmD+.

UPDATE: A key point of emphasis in the PharmD+ initiative is to adjust the core pharmacy curriculum to provide students with greater flexibility to focus on specific career paths within pharmacy.

One of the areas being explored is the bundling of designated professional electives to create pathways leading to certificates. The coupling of a certificate and a Pharm.D. degree will provide students with a level of expertise beyond the “standard” Doctor of Pharmacy, thereby creating a point of differentiation for ACPHS students when competing with graduates from other schools.

The Vermont Campus will refine this approach further by developing new courses focusing on primary care and working with the medically underserved. This curricular focus will provide graduates who choose the primary care option with the ability to more quickly transition into settings such as physician offices and ambulatory care clinics while at the same time helping meet the expanding need for primary care services.

As part of this initiative, the College’s Vermont Campus is also piloting a longitudinal community pharmacy Introductory Pharmacy Practice Experience (IPPE) with a small cohort of students. Instead of the IPPE taking place in the summer as it does now, the College is considering offering the IPPE during the spring semester so that students can better connect their classroom work and their practice experiences. Based on the positive feedback from the first group of students to test this model, a decision has been made to expand the program for the 2016-17 academic year.

The College’s two student operated pharmacies (see page 7) will offer additional integrated learning opportunities – ranging from counseling patients to running a business. These experiences will not only enhance a student’s education, but it will provide them with benefits that will extend throughout their careers.

2. ENHANCING ACADEMIC PROGRAMS, EXISTING AND NEWOBJECTIVE: We need to think strategically about which pro-grams in addition to pharmacy we want to emphasize, i.e., which ones will attract students and provide the greatest opportunities

for our graduates. To be a sustainable, vibrant institution, we need at least two large undergraduate degree programs (with 100 students or more) and one large graduate program (50 students or more). These programs need to be aligned with our core strengths and the pharmacy program. Our conversation will define the best prospects for programmatic enhancement and growth.

UPDATE: In spring 2016, the College announced that it would be adding a B.S. program in Public Health, offering a strong com-plement to the current program mix focused on human health and health care. Students will be eligible to enroll in the Public Health program beginning in fall 2016.

In conjunction with the introduction of the B.S. in Public Health, a new Department of Population Health Sciences was created as part of a strategic realignment for the College. The new depart-ment will house the B.S. in Public Health and the existing M.S. in Health Outcomes Research, a pairing that links two programs with natural synergies and strong potential for growth.

In addition to these efforts, ACPHS is developing online certif-icate programs targeting emerging skill sets being sought by employers in the current health care and research environment. Proposed disciplines for graduate certificate programs include Nanomedicine, Pharmacovigilance (Drug Monitoring and Safety), Regulatory Science/Affairs, and Economics of Healthcare. The first certificate courses are expected to be offered beginning in the 2016-17 academic year.

Plans include the ability for individuals to pursue a single certificate program or combine multiple certificates to earn a master’s degree.

3. CENTERS OF EXCELLENCEOBJECTIVE: Centers of Excellence provide a focus for faculty scholarship, research, and pedagogical innovation. They also provide a focus for fundraising opportunities. A Center of Excellence will consist of a cluster of faculty working on a com-mon overarching problem. Centers can house endowed chairs, professorships, lecture series, core facilities, grant opportunities, and student research opportunities. Centers will foster interac-tions that allow faculty and students to work in interdisciplinary collaborative teams. Our strategic conversation has explored the themes and sustainable models for these Centers.

UPDATE: The most efficient and effective way to establish Centers of Excellence at a small college is to build out from existing areas of strength. In 2015, the College asked faculty and staff to submit ideas that had the potential to become Centers of Excellence.


Following review of the proposals, two Centers of Excellence concepts have been selected for development. One proposal is focused on Epigenetic Studies; the second proposal centers around Anti-Microbial Drug Resistance. Each of these disciplines includes an existing foundation of ACPHS faculty experts with demonstrated research achievements in the field.

The College next plans to bring in an external consultant to work with the groups to refine the mission and operation of each Center. The groups have also submitted a “fundraising” whitepaper that articulates to a non-scientific external audience the vision and need for their Center.

These activities are viewed as developmental steps that will eventually lead to the launch of two Centers of Excellence, and ultimately, a stronger research environment at ACPHS.

4. THE STUDENT EXPERIENCEOBJECTIVE: We need to continue our work on developing a vibrant campus community. We need to build activities that create a strong interface between academic affairs and student affairs. Co-curricular and extra-curricular activities must link what happens in the classroom with what happens outside the classroom, providing a holistic student experience. Our conver-sation will explore how we can build this type of experience and how we can enhance our campus life. We will explore the human, physical, and technological infrastructure requirements to develop such a student experience.

UPDATE: To create the best possible experience for its stu-dents, a College must offer a complementary mix of academic and non-academic programming. Advising and mentoring play key roles in helping ensure the ideal balance is achieved for each student.

During the 2015-16 academic year, the College began offering new monthly training sessions for faculty advisors to help refine their counseling and advising skills. In parallel with this effort, a “Coffee Talk” series was launched for first year students. These informal discussions provide a relaxed setting for students to discuss anything on their mind with a member of the Student Affairs staff.

In the area of mentoring, one new program was kicked off and another one expanded. A new initiative launched in response to student feedback uses the LinkedIn platform to connect stu-dents with alumni. The initial feedback from both students and alumni on this effort has been very positive. Additionally, the College’s renewed effort to increase the number of peer mentors on campus resulted in 140 applications for 89 positions.

The response allowed every student seeking an upperclass student mentor to be matched with one, including all students on the Vermont Campus.

Looking ahead, the College will be pursuing a prestigious Community Engagement Classification from The Carnegie Foundation. To receive this designation, institutions must demonstrate, among other things, how they “prepare educated, engaged citizens; address critical societal issues; and contribute to the public good.”

5. CORPORATE RELATIONS AND THE TEACHER-CONSULTANT MODELOBJECTIVE: ACPHS has had strong historical ties to various sectors of pharmacy and the pharmaceutical industry. We need to institutionalize these ties in more formal ways and provide greater experiential learning access to industry for our students. Our practices involving rotations, internships, fellowships, and residencies need to be aligned. Strategic partnerships with specific organizations and corporations need to be developed in an intentional manner. As these partnerships grow, there will be opportunities for faculty and student consulting projects, and we need to build the business development infrastructure to support this activity. Our strategic conversation will center on how we build these corporate relations and the sectors on which we will focus.

UPDATE: Three key initiatives have been identified as vehicles for building and enhancing the College’s ties with businesses and corporations: (1) Fellowships/residencies/intern-ships that split between ACPHS and the corporate partner, (2) ACPHS educational programs or certificate offerings (in-person and online) for employees at these institutions and organizations, (3) Business consulting services that would be performed by students under the guidance of ACPHS faculty and staff.

Following the establishment of these three areas of focus, a follow-up survey was sent out to faculty and staff at the College. More than 50 individuals responded that they would be interest-ed in participating in one or more of these initiatives, with each identifying specific areas of interest and strength.

We have decided to first target corporations that are local to our campuses and those which we have pre-existing relationships. Five companies have been identified as potential partners for one of the above mentioned initiatives.

Feedback from these initial outreach efforts will be used to further refine the College’s corporate relations strategy as we explore additional partners and opportunities.


H E A LT H C A R E O F N E I G H B O R H O O D T H E F A C E


H E A LT H C A R E T H E F A C E

ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES announced plans in 2015 to launch two not-for-profit community pharmacies in medically underserved areas of the Capital Region. The first pharmacy - College Hometown Pharmacy - opened in March 2016 in the Hometown Health Centers clinic in Schenectady, NY. The second pharmacy, College Parkside Pharmacy, will open in summer/fall 2016 in the South End of Albany.

Each pharmacy will offer the dual benefit of (1) providing a distinctive and innovative experience for ACPHS students and (2) improving access to pharmacy and health care services for members of the local community.

MEETING AN EDUCATIONAL NEEDThe pharmacies will allow student pharmacists to develop and refine their advanced practice skills. As full-service pharmacies, they will include point of care screening services coupled with associated disease state counseling.

Under the supervision of a licensed pharmacist, students will have opportunities to expand their patient counseling skills in areas that may include:

n Anticoagulation Managementn Medicare Part D Plan Findern Blood Pressure Screeningn Disease Management and Preventionn Medication Therapy Managementn Cholesterol Screeningn Self Caren Osteoporosis Screeningn Immunization Therapyn Wellness Counseling

In addition to the clinical skills needed to be a successful pharmacist, students will learn the essential business skills required to successfully manage a pharmacy. The ACPHS pharmacies will provide hands on experience in revenue analysis, inventory turnover analysis, break-even analysis, and pharmacy cash-flow analysis. Through their experiences in the pharmacies, students will be better prepared to “think like entrepreneurs,” proactively seeking out opportunities not only for operational efficiencies and growth but for creative health care business models.

The additional time spent working with real patients in real clinical settings combined with the managerial, problem solving skills required to run a pharmacy will ensure ACPHS students are Beyond Practice Ready when they graduate.

MEETING A COMMUNITY NEEDThe unfortunate truth is that the nation’s lower income commu-nities do not attract as many retailers and providers of services as more affluent areas. Pharmacy is no exception. Medical and public health services also lag in these areas.

A study in the November 2014 issue of Health Affairs found that from 2000-2012 the number of pharmacies in predominantly Hispanic and black communities of Chicago declined by 17% and 11% respectively. Over that same period, the number of pharma-cies in Chicago’s white communities increased by 30%.

According to the study’s authors, the exodus of pharmacies from underserved areas has led to the creation of “pharmacy deserts.”

Furthermore, the National Center for Health Statistics reports that in 2013, 8.4% of primary care physicians would not accept new patients. The acceptance of Medicaid patients is even more severe with 35% of physicians not taking new Medicaid patients. Lower income areas with predominantly Medicaid populations are clearly not getting the primary care services they need.

MEETING FUTURE NEEDSIn addition to dispensing medications and providing related services, each pharmacy will serve as a “collaboratory” where the College will partner with local health care providers to joint-ly offer an expanded range of clinical services. The pharmacies will be “convenient care” centers much like commercial retail clinics, but will offer a broader range of services associated with patient wellness.

The ability to share space with a physician or nurse practitioner, for example, will ensure patients have convenient access to multi-ple levels of health care. It will also help prepare students to serve as part of a health care team, one of the core tenets of a patient-centric approach to care.

Plans for the student operated pharmacies include space where students will be able to host educational forums about certain health topics or disease states, thereby expanding the learning experience to include a component of public health.

The ACPHS student operated pharmacies will serve as pro-totypes for health care in disadvantaged areas of the Capital Region. They will avoid the expansion of pharmacy deserts by allowing for improved access to prescription medications and preventive health care services in medically underserved areas.

Over time, the College envisions the pharmacies emerging as the “face of neighborhood health care.”

T H E C O L L E G E ’ S T W O S T U D E N T O P E R A T E D P H A R M A C I E S W I L L P R O V I D E D I S T I N C T L E A R N I N G

O P P O R T U N I T I E S F O R S T U D E N T S W H I L E P R O V I D I N G M U C H N E E D E D S E R V I C E S T O L O C A L C O M M U N I T I E S .


A H E A D

S T E P O N E

A H E A DACPHS PRESIDENT’S REPORT 9

ROB DICENZO, PHARM.D., BCPS, FCCP, EMBODIED the attitude of Beyond Practice Ready long before the term was coined by ACPHS President Greg Dewey.

The Senior Associate Dean of Academic Affairs and Operations – who was promoted to the newly created position at the start of the 2015-16 academic year – has consistently worked throughout his career to keep pace, and stay one step ahead of, the changes in his profession.

After years of working as a clinical pharmacist at Rochester General Hospital, Dr. DiCenzo decided to expand his clinical skills and practice opportunities by pursuing his Doctor of Pharmacy at Albany College of Pharmacy and Health Sciences. Remember, this was a time when the Pharm.D. was an advanced degree, not the minimum requirement that it is today for entry level pharmacists.

As he was finishing up his Pharm.D., Dr. DiCenzo received an offer from the University at Buffalo (where he received his bach-elor’s degree) to complete a two year fellowship in Antiretroviral Pharmacology and Pharmacometrics. “The opportunity wasn’t something I had planned for, but I figured it could only help me,” says Dr. DiCenzo. And it did.

The fellowship became a springboard for his entrée into academia. He received an academic appointment as an Assistant Professor at the University at Buffalo in 2000 and began developing a research program in the Infectious Disease Division of the Department of Medicine at the University of Rochester Medical Center.

It was an historic time in the practice of medicine and pharmacy as researchers were beginning to harness the power of combina-tion therapies in treating HIV/AIDS patients.

Dr. DiCenzo explains, “We now had these good therapies, but we still needed to understand how best to dose patients in order to increase adherence, decrease adverse events, and optimize individual patient outcomes. This was particularly difficult when patients had handfuls of pills to take each day. A lot of the research that I did centered around optimizing these patients’ medication regimens.”

In 2008, he left his position as Associate Professor at the University at Buffalo to join the founding team at the St. John

Fisher College Wegmans School of Pharmacy as the Director of Experiential Education. He was at the school for three years before being named Chair of the Department of Pharmacy Practice at ACPHS.

Without necessarily planning it, his range of previous experiences – clinical pharmacist, fellow, educator, administrator, researcher – had coalesced to provide him with the ideal background for the Chair position. You might say he was Beyond Practice Ready.

Dr. DiCenzo arrived at ACPHS in 2010 during a transitional time for the College, and in particular, the Department of Pharmacy Practice. The department had not had a permanent leader for nearly a decade, and there was now a second Department of Pharmacy Practice on the Vermont Campus which was headed by its own chair.

“My focus at that time was to provide stability for the department while working to facilitate better integration between the two campuses,” he says. “Working with Dean Angela Dominelli, we rolled out a plan to merge the two departments into a single unit during the 2012-13 academic year.”

Fast forward to today and the two departments have been suc-cessfully combined, with Vermont now benefitting from a dedicated Vice Chair position. Dr. DiCenzo, however, continues to look ahead.

In his new role, he will be focused on the mission and goals of both the School of Pharmacy and Pharmaceutical Sciences and the College. Initiatives will include helping define and implement the PharmD+ initiative (see page 4); working closely with faculty to incorporate the new active learning classrooms into the curriculum; and identifying opportunities to integrate the student operated pharmacies into coursework, practice experiences, and other curricular and co-curricular activities.

And if that’s not enough, this spring Dr. DiCenzo began a two year term as President of APhA’s Academy of Pharmaceutical Research and Sciences which includes a place on their Board of Trustees. He acknowledges it will be a demanding role, but he is motivated by the opportunity to “keep on the cutting edge of what’s happening in our profession.” After all, it’s something he’s been doing his whole career.

B Y C O N T I N U I N G T O C H A L L E N G E H I M S E L F , S E N I O R A S S O C I A T E D E A N R O B D I C E N Z O

H A S H E L P E D R E D E F I N E W H A T I T M E A N S T O B E A P H A R M A C I S T.


S T A N D I N G U P F O R S T U D E N T S

S T A N D I N G U P F O R


WALK INTO WENDY NEIFELD WHEELER’S OFFICE any time of day, and one thing will strike you immediately. She’s standing.

She uses a standing desk to help keep her back healthy, but it provides an appropriate metaphor for her position as Dean of Students. She can be counted on to stand up for the needs and interests of each student at the College.

Advocating for students is nothing new for Dr. Neifeld Wheeler, but doing it at ACPHS is a change. Prior to joining the College last summer, she had spent the previous 29 years at the College of St. Rose.

Her roles there included: Director of Residence Life, Assistant Director of Counseling and Psychological Services, Coordinator of the Risk Assessment and Alcohol Awareness Project, Chief Judicial Officer, and Director of Parent and Family Relations.

She readily admits that the St. Rose community was like family, and while she had occasionally explored other opportunities through the years, it was a place that felt like home.

Despite her known feelings for St. Rose, she was contacted by a former colleague last spring to see if she would be interested in the Dean of Students opening at ACPHS. “I thought, ‘I’ll take a look,’” she says. “But the more I learned, the more I realized that this was really an incredible opportunity. It had so many pieces of the work that I had done before and other things I was interested in doing.”

She decided to formally apply for the position, and each step along the way she became more excited about joining ACPHS. “Every time I met with a person from the College, visited the campus, or communicated with someone from the search com-mittee, I felt a tug. It was a feeling that ‘you can do more than just fit in here, you can make a contribution.’”

Near the end of the interview process, Dr. Neifeld Wheeler gave a presentation in which all members of the ACPHS community

were invited to attend. A young female student approached her following the presentation and explained that she had attended each of the candidates’ talks and that Dr. Neifeld Wheeler’s stood out from them all. She added, “You can make a difference here.”

It was a powerful moment for Dr. Neifeld Wheeler who now meets regularly with the young woman to discuss issues related to the College and beyond. “I was taken aback with her words, her thoughtfulness, and her courageousness. I came home that day and told my husband that it didn’t matter whether or not I was offered the position. The fact that this student made it a point to tell me what she did – that was more important to me than the ultimate outcome.”

Clearly, this student was not the only one impressed by Dr. Neifeld Wheeler. She was offered the position, accepted, and began on July 1, 2015.

In less than a year, Dr. Neifeld Wheeler has quickly embraced the Beyond Practice Ready approach. One of her top priorities is to encourage students to reach out to members of the local community in new and different ways. This community engagement philosophy will involve broadening education and programming surrounding LGBT needs, homelessness, and other social issues. In Dr. Neifeld Wheeler’s words, “We want to pre-pare our students for working with more disenfranchised clients” – an effort that aligns well with one of the core objectives of the student operated pharmacies.

She will also be leading the charge for the College to obtain the Carnegie Foundation’s Community Engagement Classification. This prestigious designation is awarded to schools with an institutional focus on community engagement.

As she reflects back today on her decision to join ACPHS, she says, “You have an innate, gut feeling when a place is the right fit. You may or may not be able to pinpoint a specific moment of realization, but you will know. I’ve lucked out with a Capital L.” So has the College.

N E W D E A N O F S T U D E N T S W E N D Y N E I F E L D W H E E L E R D R A W S U P O N H E R D I V E R S E

B A C K G R O U N D T O P R O V I D E A C P H S S T U D E N T S W I T H G U I D A N C E A N D S U P P O R T.


I N D U S T R I A L E V O L U T I O N

E V O L U T I O N


DEREK PETERSON’S GOAL HAD ALWAYS BEEN TO work in the pharmaceutical industry as a Medical Science Liaison. He pursued the Pharm.D. degree on the ACPHS-Vermont Campus (graduating in 2015) because he knew it would prepare him well for such a role.

For those unfamiliar with the position, a Medical Science Liaison (MSL) meets regularly with physicians, helping ensure products are being used effectively and serving as a resource for scientific related questions and information.

To help further prepare himself (and other classmates) for a career in industry, Dr. Peterson started a student chapter of the Industry Pharmacists Organization near the end of his third professional year. Despite the fact that he would soon be heading out on his fourth year rotations, Dr. Peterson still played an active role in the group’s first year activities, making presenta-tions and arranging for guest speakers.

Everything was proceeding according to plan until his final year as a pharmacy student when a rotation at the headquarters of Amgen set him on a different path. “You tend to work alone as an MSL, and I realized at Amgen how much I liked working in a team environment,” he says. “I also saw the benefit of being involved with the planning and brand strategy that takes place in-house, and how valuable it is to have that experience before heading out into the field as an MSL.”

Following the Amgen rotation, Dr. Peterson reset his sights from a field-based industry fellowship to one focused on in-house functions. He applied to the Rutgers Pharmaceutical Industry Fellowship program – the biggest (and most competitive) program of its kind for the pharmaceutical industry – and was accepted into the two-year program. He is now a Postdoctoral Fellow at Bristol-Myers Squibb (BMS) in Princeton, New Jersey.

There are approximately 120 fellows at nearly 20 different phar-maceutical companies in the Rutgers program, and in addition to their day-to-day responsibilities, the group meets every two weeks to participate in a Professional Development Series. Much as he did at ACPHS, Dr. Peterson has taken an active role with this group, serving as co-chair of the Series’ committee, where he helps choose discussion topics for each meeting, plan the content, and recruit guest speakers.

During his first year at BMS, he is working in the Immunoscience therapeutic area, helping support Orencia, a drug for rheumatoid

arthritis. He will spend six months apiece with the Medical Information and Medical Strategy teams.

As part of the Medical Information team, he will split his time between responding to “medical information requests” (inquiries from health care practitioners) and “promotional review,” which focuses on customer-facing communications.

“When you are able to watch something go from concept generation to the customer’s hands, you develop an appreciation for how scrutinized the process is. I knew it was an extremely regulated industry, but I had no idea how much effort goes into making sure information is transparent and balanced.”

In Medical Strategy, he will work with colleagues to determine the various medical meetings the Orencia team will attend in 2016, and more specifically, what they will be discussing and presenting at these meetings. He will also do competitive research, assessing new medications coming to market and determining if/how they will compete with BMS products.

Dr. Peterson will transition to a new therapeutic area in July 2016 – Immuno-Oncology Publication Strategy – where he will focus on high impact journals, helping manage the publications for a specific product in the BMS portfolio.

He was also recently selected for the honor of serving as one of two Co-Chiefs for the entire fellowship program. In this multi-fac-eted leadership role, his responsibilities will include promoting and encouraging the growth of each of the 160 fellows in next year’s program.

It’s a lot to manage, but he is often reminded of why he does it all. “We have patients who come to our Professional Development Series, and you listen to their stories,” he says. “It almost brings tears to your eyes when you hear how they have benefitted from these products. It reminds you why you are coming to work every day. It’s all about the patients.”

Dr. Peterson hasn’t closed the door on becoming an MSL one day, but for now, he’s focused on completing his fellowship and seeing what type of in-house opportunities are available to him in industry. Regardless of what he decides to do, there’s no question that he will be Beyond Practice Ready when he begins the next phase of his career.

A S A P O S T D O C T O R A L F E L L O WA T B R I S T O L - M Y E R S S Q U I B B ,

D E R E K P E T E R S O N ’ 1 5 I S B U I L D I N G T H E F O U N D A T I O N F O R A C A R E E R

I N T H E P H A R M A C E U T I C A L I N D U S T R Y.


P E R C E N TT O P O N E

T H E


A S S O C I A T E P R O F E S S O R K A R E N G L A S S ’ S R E C E N T N I H G R A N T S U B M I S S I O N R E C E I V E D T H E

H I G H E S T A C H I E V A B L E S C O R E , B U T T H E B I G G E R S T O R Y M A Y B E T H E I M P A C T O F H E R R E S E A R C H .

THE LAST TIME KAREN GLASS, PH.D., WAS PROFILED in the President’s Report, the Associate Professor on the Vermont Campus had just received her first research grant from the National Institutes of Health (NIH).

The findings generated over the following three years demon-strated more than enough promise for her to receive continued funding. Yet, despite the quality of her research and potential impact of the work on a variety of disease states, there were no guarantees when she began working on the follow-up grant submission in 2015.

Consider that between 2005-2014, the overall budget for the National Institutes of Health decreased by nearly 20% after adjusting for inflation. The competition for NIH research dollars is more intense than perhaps at any time in the Institute’s history, meaning there are excellent investigators working on some of our most pressing health threats who are unable to obtain federal funding.

At times like this, it pays to be Beyond Practice Ready.

Dr. Glass’ most recent submission was bolstered by six peer- reviewed publications based on her research from the original grant, an above-average number of journal articles for this type of grant, which is categorized by NIH as an R15.

She has also worked to cultivate a network of collaborators at institutions that include the University of Vermont (where she earned her Ph.D.), the University of Texas MD Anderson Cancer Center, and England’s Newcastle University. “Science today really has to be a team effort because the reality is that no lab can do everything,” says Dr. Glass. “You can make a more complete story by working together.”

Her accumulated credentials, combined with the encouraging results of her initial research findings, gave Dr. Glass reason to be optimistic about being awarded a second grant. But in the current funding environment, nothing can be taken for granted.

So when Dr. Glass received approval from NIH on a three-year grant totaling $384,000 it was an impressive accomplishment. But it was made even more noteworthy when she learned that her submission had earned a score of 10. Ten is the highest score one can receive for an NIH grant submission, an achievement that ranks Dr. Glass in the top 1% of all grant applications that NIH scores.

The score speaks volumes for the quality of Dr. Glass’ research, but it also reflects the importance of the work she is doing. The focus of her efforts centers on bromodomains which are small protein modules contained within larger protein structures. Scientists have identified approximately 60 human bromo-domains and organized them into eight families.

Bromodomains play a critical role in the body by influencing the expression of genes in our cells. These interactions drive a range of biological processes, including in some cases, the onset or advancement of disease.

Scientists have long understood the influence and importance of bromodomains, but until recently, they were largely thought to be inaccessible as drug targets. In 2010, however, two separate labs demonstrated that small molecules could be developed to inhibit the actions of bromodomains. These findings have fueled great interest in bromodomains as potential new drug targets for preventing or reducing the risk of disease.

Each of the 60 bromodomains has been identified and mapped, but researchers still do not know a lot about their biological function. Dr. Glass’ first grant focused on a single bromodomain in Family IV named BRPF1.

In the new grant, Dr. Glass will study all seven bromodomains in Family IV. The focus of these efforts will be to determine whether there is a consistent method for how the bromodomains in Family IV function.

“While bromodomains offer great promise as potential drug tar-gets, it is difficult to move forward with the development of new drugs until we better understand the biological function of each bromodomain,” said Dr. Glass. “Once, however, we are able to better document how bromodomains work, our ability to develop next generation drugs targeting cancer and other diseases will improve significantly.”

The research success of Dr. Glass is also good news for ACPHS students, several of whom assist her in the lab. “Pharmacy students have a great background for research as a result of coursework in disciplines such as math, physics, and chemistry,” she says. “I’m impressed by how quickly they hit the ground running once they begin working in the lab.”

This ability to draw upon their education, adapt to new situa-tions, and contribute to a team will no doubt serve these gradu-ates well throughout their careers – just as it has for Dr. Glass.


C O M M U N I C A T I O NI L L

C O M M U N I C A T I O NACPHS PRESIDENT’S REPORT 17

A S S O C I A T E P R O F E S S O R P A U L D E N V I R B E L I E V E S T H A T E F F E C T I V E

P R O V I D E R - P A T I E N T C O M M U N I C A T I O N I S K E Y T O I M P R O V I N G H E A LT H O U T C O M E S .

PAUL DENVIR, PH.D., ARRIVED AT ACPHS SIX YEARS AGO admittedly feeling a bit out of place. Without the benefit of a group of like-minded peers, the communication scholar began talking with clinical faculty at the College about potential collaborations, and in the process, he found a new focus for his research. Today, Dr. Denvir is applying his interest in provider-patient interaction to a different and understudied type of provider – the pharmacist.

If you look at the arc of Dr. Denvir’s career, it might appear he arrived at this point after following a precise plan, but he readily admits that was never the case. “I believe a lot of life is capitalizing on serendipitous opportunity. Being attuned to what is available to you. Explore. Taste. Try. I try to tell this to students all the time.”

An advanced degree was never even on his radar until a faculty member suggested he consider graduate school while he was a senior at the College of St. Rose. He decided to continue his education at the University at Albany where he received a mas-ter’s degree in Interpersonal and Intercultural Communication and then eventually a Ph.D. in Sociology (with a concentration in Health Communication).

While at UAlbany, he began working closely with Dr. Anita Pomerantz, one of the foremost authorities in the field of Conversation Analysis. This emerging field closely examines the details and dynamics of social interaction, emphasizing the significance of word choices, intonation patterns, and nonverbal cues in communication outcomes.

“At the time I was in school, there were a lot of people who were using Conversation Analysis to ‘improve the toolbox.’ I was more interested in using the tools to address problems instead of mak-ing more tools. That was a big turn for me professionally, and I’ve really embraced that approach here at ACPHS,” he explains.

Working with both students and faculty members such as Drs. Jeffrey Brewer and Katie Cardone of the Department of Pharmacy Practice, Dr. Denvir has been recently studying the communication skills required to successfully engage patients in Medication Therapy Management (MTM).

From a communication perspective, there are three parts to an MTM consultation. The first, and often most difficult phase, is per-suading the patient to participate in a medication review. Once the patient agrees to an MTM consultation, the pharmacist has to successfully elicit information about their symptoms, medication usage, lifestyle, and other factors that may impact their health and wellness. Lastly and most importantly, the pharmacist must help the patient understand the critical importance of adherence in any future medication regimen.

“For me, adherence is the heart of matter,” he says. “If the patient struggles with adherence, then all of the quality work that leads up to this point goes out the window. My training gives me a way to assess provider-patient communication and produce recom-mendations on how to improve these engagements.”

Dr. Denvir will also play a key role in the College’s new Bachelor’s in Public Health program which evolved from the former B.S. in Health and Human Sciences. The new program will increase the emphasis on the social and behavioral aspects of public health, including elements of health outcomes research and data analytics. The program faculty have been using the phrase “scientifically grounded, socially engaged” as a compass point for the new direction.

He believes the Public Health program will appeal to a wider range of students. “I talk with many prospective students who have a strong sense of altruism and would like to direct those interests into patient care, but who may be uncomfortable with the one-to-one dynamic. I tell them to start thinking about a community or a population as their patient. That’s when they see another avenue open up to them.”

The term Beyond Practice Ready means different things for different people. For Dr. Denvir, it means helping students develop outstanding patient communication skills, not just outstanding clinical care skills. “Communication is not some ideal overlay that you add on. It’s a skill set, and it’s every bit as important as your ability to order and interpret the results of a test.”


C L I N I C A L

S T U D Y


N A B E E L A A H M E D ’ 1 5 I S P U R S U I N G A T W O -Y E A R R E S I D E N C Y A T N Y U L A N G O N E M E D I C A L C E N T E R

W I T H T H E G O A L O F B E C O M I N G A N I N F E C T I O U S D I S E A S E S C L I N I C A L P H A R M A C I S T.

NABEELA AHMED, PHARM.D., STILL RECALLS THE name of the young woman who hosted her Admissions tour at ACPHS. “Her name was Tasmina. I remember her being very motivated and excited to begin her career as a pharmacist. Her enthusiasm really captured me.”

At the time, Dr. Ahmed was like many high school students who tend to think of pharmacy as something practiced only in a com-munity setting. It wasn’t until her entrance into the professional program that she began to learn about the range of opportuni-ties available to pharmacists.

“I was not aware of the field of clinical pharmacy until my P1 year,” the Class of 2015 graduate admits. “As I began to talk with clinical faculty members at the College and learned more about this area, something clicked for me. I suddenly knew that this was what I wanted to do.”

She quickly recognized that most of the clinical faculty at the College were residency-trained. If this was an area that she intended to pursue, she knew that she would need to begin taking steps to prepare herself for a pharmacy residency. That’s when fate intervened.

Dr. Ahmed saw a posting on a College bulletin board that Samaritan Hospital in Troy was looking for pharmacy interns. She applied during her P2 year and was selected for an intern-ship working 16-20 hours per week at the hospital. She was able to work side-by-side with the hospital’s two clinical pharmacists (both of whom were residency-trained), and the experience helped cement her career direction.

She also took advantage of opportunities to expand her skill set by joining professional organizations on campus. She was an active member of the Student Society of Health-system Pharmacists (SSHP), as well as the student chapters of the American College of Clinical Pharmacy (ACCP) and the American Pharmacists Association (APhA-ASP).

Through her memberships in those organizations, Dr. Ahmed par-ticipated in activities and programs related to poison prevention, bone health, care screenings, brown bag reviews, and more. In addition to providing valuable services to the community, these

experiences also helped Dr. Ahmed refine her skills in areas such as public speaking, making presentations, networking, and working with patients.

As she was building this impressive C.V., she recognized that research was an area where she was lacking experience. So during her P2 year, she assisted in the lab of Associate Professor Nimish Patel, an infectious diseases (ID) pharmacist at the College.

All of these activities made for a busy schedule, but she loved what she was doing, and she was accumulating the types of experiences needed to make herself a strong applicant for a pharmacy residency.

Whether she realized it or not at the time, she was also taking steps to make herself Beyond Practice Ready. “To succeed as a resident, you must be well rounded in a variety of areas – patient care, didactic, research, administrative. I tried to get myself exposed to every aspect of the role before embarking on the process.”

When she learned that she had been selected for a residency at New York University Langone Medical Center, it was a dream come true for Dr. Ahmed, who grew up in the nearby borough of Queens.

“This residency is everything I expected and much more. You work hard. You have to be independent. And there is definitely a lot to balance,” she says. “But a residency has to be rigorous because it is only one year, and you have to be able to handle any situation that may arise.”

Nabeela’s long term goal is to become an ID clinical pharmacist. She will take another step in that direction next year, as she recently accepted a position as the Postgraduate Year Two (PGY2) Infectious Diseases resident at NYU.

Dr. Ahmed has worked hard to get where she is today, but she also credits the faculty at ACPHS as being instrumental to her success. “I was very fortunate to work with great faculty during my time as a student,” she says. “They told me what to do to stand out, and all of their recommendations were right on the mark. I credit their guidance and support with helping me achieve my goals.”

F A C U LT Y P E R S P E C T I V E S

“ …A graduate of ACPHS is able to walk into a health care setting and, from day one, stand out as an actively engaged colleague, clinician, or scientist.”

ALLISON BURTON-CHASE

BASIC AND SOCIAL SCIENCES

“ ...STUDENTS ARE PREPARED TO WORK IN THE REAL WORLD WITH REAL PEOPLE, GOING ABOVE AND BEYOND THE BASICS.”

WENDY PARKER, BASIC AND SOCIAL SCIENCES

“ . . .STUDENTS POSSESS INSIGHTS INTO THE VALUE OF SEEKING, EVALUATING, AND INTEGRATING NEW KNOWLEDGE OR SKILLS AS PART OF THE HEALTH CARE TEAM.”

GINA GARRISON, PHARMACY PRACTICE

“ …INSTEAD OF TRAINING STUDENTS TO PRACTICE A PROFESSION, WE ARE EDUCATING THEM TO GO BEYOND: TO ENGAGE IN IT, TO ACCEPT CHALLENGES, TO IMPROVE IT, AND TO GROW INTELLECTUALLY.”

LISA VINES, HUMANITIES AND COMMUNICATION

“ ...Students are not just prepared to practice, but prepared to excel in practice.”

KATE CABRAL, PHARMACY PRACTICE

“ …STUDENTS WILL GRADUATE FROM A PROGRAM WITH A SET OF KNOWLEDGE, AND, ONCE IN THE WORKFORCE, THEY WILL BE ABLE TO ADD TO THIS BODY OF KNOWLEDGE USING THE SKILLS THAT THEY HAVE LEARNED.”

JEFF VOIGT

PHARMACEUTICAL SCIENCES

“ …Our students have the skills to be self-directed, life-long learners who are both adaptable and innovative in their approaches to optimizing health outcomes in a changing environment.”

SARAH SCARPACE, PHARMACY PRACTICE

“ …GRADUATES ARE READY TO FULLY PARTICIPATE IN THE CHANGING HEALTH CARE DELIVERY SYSTEM, ADAPTING TO AN EXPANDED ROLE THAT WILL IMPROVE THE HEALTH OF THEIR PATIENTS.”

BOB HAMILTON, PHARMACY PRACTICE

BEYOND PRACTICE READY MEANS…


S C H O L A R LY

R E P O R TA C T I V I T Y

J A N U A R Y 1 , 2 0 1 5 – D E C E M B E R 3 1 , 2 0 1 5



D E P A R T M E N T O F P H A R M A C Y P R A C T I C E PUBLICATIONS

PEER REVIEWED ARTICLES

Jeffrey BrewerDenvir P, Brewer J. “How dare you question what I use to treat this patient?”: Student pharmacists’ reflec-tions on the challenges of communicating recommen-dations to physicians in in-terdisciplinary health care settings. Health Communi-cation, 2014, 30(5):504-512, PMID: 24971910.

Katie CardoneCardone K, Chen W, Grabe D, Batzold A, Manley H, Lodise TP. Evaluation of the pharmacodynamic profile of commonly used intravenous vancomycin dosing schemes in patients on automated peritoneal dialysis. Journal of Anti-microbial Chemotherapy, 2014, 69(7):1873-1876, PMID: 24722842.

Jo CarrenoWerth B, Carreno J, Reveles K. Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996-2010. American Journal of Infection Control, 2015, 43(5):465-468, PMID: 25783865.

Carreno J, Kenney R, Bloome M, McDonnell J, Rodriguez J, Weinmann A et al. Evaluation of pharmacy generalists performing antimicrobial stewardship services. American Journal of Health-System Pharmacy, 2015, 72(15):1298-1303, PMID: 26195656.

Jennifer CerulliCerulli C, Nichols-Hadeed C, Raimondi C, Stone J, Cerulli J. Facilitating intimate partner violence education among pharmacy students: What do future pharmacists want to know? Currents in Pharmacy Teaching and Learning, 2015, 7(3):283-291, PMID: 25937853.

Gina GarrisonGarrison G, Baia P, Canning J, Strang A. An asynchro-nous learning approach for the instructional compo-nent of a dual-campus pharmacy resident teach-ing program. American Journal of Pharmaceutical Education, 2015, 79(2):29, PMID: 25861110.

Michael KaneSaroka RM, Kane MP, Busch RS, Watsky J, Hamilton RA. SGLT-2 inhibitor therapy added to GLP-1 agonist ther-apy in the management of T2DM. Endocrine Practice, 2015, 21(12):1315-22.

David KileRudd K, Goss J, Engle A, Kile D. Increasing hos-pital pharmacist clinical competence in intensive pharmacotherapeutics using a novel pharmacist clinical educational pro-gram. Hospital Pharmacy, 2015, 50(9):776-782.

Nicole LodiseRafie S, Shealy K, Borgelt L, Forinash A, Shrader S, Koepf E, McClendon K, Griffin B, Horlen C, Karaoui L, Rowe E, Lodise NM, Wigle P. Roles of the pharmacist in the use of safe and highly effective

long-acting reversible contraception: An opinion of the women’s health prac-tice and research network of the American College of Clinical Pharmacy. Pharmacotherapy 2014; 34 (9): 991-999.

McBane SE, Borgelt LM, Barnes KN, Westberg SM, Lodise NM, Stassinos M. Use of compounded bi-oidentical hormone therapy in menopausal women: An opinion statement of the women’s health practice and research network of the American College of Clinical Pharmacy. Pharmacotherapy 2014; 34(4): 410-423.

Thomas LodiseKauf TL, McKinnon P, Corey GR, Bedolla J, Riska PF, Sims M, Jauregui-Peredo L, Friedman B, Hoehns JD, Mercier RC, Garcia-Diaz J, Brenneman SK, Ng D, Lodise T. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of dapto-mycin versus vancomy-cin for the treatment of complicated skin and skin structure infection. BMC Infectious Diseases 2015 Nov 7;15:503. doi: 10.1186/s12879-015-1261-9. PubMed PMID: 26547411; PubMed Central PMCID: PMC4637139.

Culshaw D, Lamp KC, Yoon MJ, Lodise TP. Duration of prior vancomycin therapy and subsequent daptomy-cin treatment outcomes in methicillin-resistant Staphy-lococcus aureus bactere-mia. Diagnostic Microbiolo-

gy and Infect Disease 2015 Oct;83(2):193-7. doi: 10.1016/j.diagmicrobio.2015.06.003. Epub 2015 Jun 11. PubMed PMID: 26184127.

Zasowski E, Bland CM, Tam VH, Lodise TP. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospi-talized patients. Journal of Antimicrobial Chemother-apy 2015 Mar;70(3):877-81. doi: 10.1093/jac/dku435. Epub 2014 Nov 6. PubMed PMID: 25381169.

Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM. Assessment of time to clinical response, a proxy for discharge readi-ness, among hospitalized patients with communi-ty-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials. Antimicrobial Agents and Chemotherapy 2015 Feb;59(2):1119-26. doi: 10.1128/AAC.03643-14. Epub 2014 Dec 8. PubMed PMID: 25487791; PubMed Central PMCID: PMC4335888.

Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, Prokocimer P. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2015 Feb;59(2):864-71. doi: 10.1128/AAC.03688-14. Epub 2014 Nov 24. PubMed PMID: 25421472; PubMed Central PMCID: PMC4335893.

Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. Association between vancomycin day 1 exposure profile and outcomes among patients with meth-icillin-resistant Staphylo-coccus aureus infective endocarditis. Antimicrobial Agents and Chemotherapy 2015;59(6):2978-85. doi: 10.1128/AAC.03970-14. Epub 2015 Mar 9. PubMed PMID: 25753631; PubMed Central PMCID: PMC4432113.

Lodise TP, Fan W, Sulham KA. Hospital admission patterns in adult patients with skin and soft tissue infections: Identification of potentially avoidable hospital admissions through a retrospective database analysis. Hospital Practice (1995) 2015;43(3):137-43. doi: 10.1080/21548331. 2015.1076325. PubMed PMID: 26224423.

Darius MasonAl-Sofiani ME, Jammah A, Racz M, Khawaja RA, Hasanto R, El-Fawal HAN, Mousa SA, Mason DL. Effect of Vitamin D sup-plementation on glucose control and inflammatory response in type II diabetic patients: double blind, randomization clinical trial. International Journal of Endocrinology and Metabolism, 2015, 13(1), PMID: 25745497.

Phelps KR, Mason DL, Stote KS. Parameters of phospho-rus homeostasis at normal and reduced GFR: empiric observations. Clinical Nephrology, 2015, PMID: 25707455.

S C H O O L O F P H A R M A C Y A N D P H A R M A C E U T I C A L S C I E N C E S


Phelps KR, Mason DL. Parameters of phosphorus homeostasis at normal and reduced GFR: theoretical considerations. Clinical Nephrology, 2015, PMID: 25685872.

Mathew RO, Mason DL, Tryniszewski T, Kennedy J. Antibody response fol-lowing boost with Hepatitis B vaccine correlates with presence of intrinsic T-regu-latory cells in hemodialysis patients. Hemodialysis International, Jun 23 2015, DOI: 10.1111/hdi.12326, PMID: 26104830.

Patrick MeekTriller D, Wymer S, Meek P, Hylek E, Ansell J. Trends in Warfarin Monitoring Practices Among New York Medicare Beneficiaries, 2006–2011. Journal of Community Health, 2015, 40(5):845-854, PMID: 26198584.

Amy Barton PaiPai AB, Grabe DW, Eisele G, Patel H, Kubotera S, Prokopienko A, Nolin T. Changes in plasma levels of asymmetric dimethy-larginine in chronic kidney disease patients treated for 8 weeks with the Vitamin D receptor agonist paricalci-tol. Journal of Research and Development, 2015, 3:2.

Jang S, Prokopienko AJ, Grabe DW, Cerulli J, Fox C, Vassalotti J, Pai AB. NSAID-avoidance education in community pharmacies for patients at high risk for acute kidney injury, upstate New York, 2011. Preventing Chron-ic Disease, Dec 18 2014, 11:E220 PMID:25523351.

Amit PaiPai MP. Treatment of bacterial infections in obese patients: How to appropriately manage the dosage. Current Opinion in Pharmacology, 2015, 24:12-17, PMID: 26119488.

White B, Lomaestro B, Pai MP. Optimizing the initial amikacin dosage

in adults. Antimicrobial Agents Chemotherapy, 2015, 59(11):7094-6, PMID: 26282426.

Hong J, Kropp LC, Johns T, Pai MP. Individual vancomy-cin dosing in obese patients: A two-sample measurement approach improves target attainment. Pharmacother-apy 2015, 35(5):455-63, PMID: 26011138. Justo JA, Mayer S, Pai MP, Soriano M, Danziger LH, Novak R, Rodvold KA. Pharmacokinetics of ceftaroline in normal body weight and obese (Classes I, II, and III) healthy adult subjects. Antimicrobial Agents Chemotherapy, 2015, 59(7):3956-65, PMID: 25896707.

Pai MP, Cojutti P, Pea F. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: A step toward dose opti-mization for the treatment of severe gram-negative bacterial infections. Clinical Pharmacokinetics, 2015, 54(9):933-41, PMID: 25850987.

Zheng HA, Truong J, Carroll F, Pai MP. Do differences between reference listed drug and generic products of Piperacillin-tazobactam affect reconstitution? Antimi-crobial Agents Chemother-apy, 2015, 59(3):1767-9, PMID: 25512410.

Nimish PatelPatel N, Assimon MM, Bruni E, McNutt LA, Mason DL. Incidence and clinical predictors of non-response to Hepatitis B vaccination among patients receiving hemodialysis: Importance of obesity. Southern Med-ical Journal, 2015, PMID: 26332483.

Patel N, Nasiri M, Koroglu A, Amin R, McGuey L, McNutt LA, Roman M, Miller CD.

Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbu-vir-containing treatment among HIV and Hepatitis C coinfected patients. AIDS Research and Human Retro-viruses, Feb 2015, 31(2):189-97, PMID: 25708155. Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, et al. A cross-sectional study comparing the fre-quency of drug interactions after adding simeprevir- or sofosbuvir-containing ther-apy to medication profiles of Hepatitis C monoinfected patients. Infectious Diseases and Therapy, 2015, 4(1):67-78, PMID: 25708155.

Britt NS, Potter EM, Patel N, Steed ME. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: A national cohort study of veterans affairs patients. Clinical Infectious Diseases, Jun 10 2015, pii: civ444, PMID: 26063715.

Sarah ScarpaceScarpace SL. Metastatic squamous cell non-small-cell lung cancer (NSCLC): Disrupting the drug treatment paradigm with immunotherapies. Drugs in Context 2015; 4: 212289. DOI: 10.7573/dic.212289.

Kimberly SkylstadGarren T, Skylstad K. Scaffolded online learning modules for milliequiva-lency and milliosmolarity calculations. Currents in Pharmacy Teaching and Learning (in press).

Aimee StrangStrang AF, Baia P. How effective are pharmacy teacher training programs? A comprehensive review of teaching and learning programs in pharmacy education. The American Journal of Pharmaceutical Education (In Press).

Baia P, Strang AF. A five year study: Pharmacy

educator motives to pursue pedagogical knowledge. The American Journal of Pharmaceutical Education (In Press).

Fuentes DG, Ogden RR, Ryan-Haddad A, Strang AF. Reframing our pursuit to work/life balance. The American Journal of Phar-maceutical Education 2015; 79(3): 34.

CASE REPORTS AND REVIEW ARTICLES

Katherine Cabral Boden WE, Padala SK, Cabral KP, Buschmann I, Sidhu MS. The role of short-acting nitroglycerin in the management of isch-emic heart disease. Drug Design, Development and Therapy 2015; 9:4793-4805.

Cabral KP, Ansell JE. The role of factor Xa inhibitors in VTE treatment. Journal of Vascular Health and Risk Management, Jan 2015; 11:117-123.

Clayton EnglishEnglish C, Aloi JJ. New FDA-approved disease- modifying therapies for multiple sclerosis. Clinical Therapeutics, 2015, 37(4): 691-715, PMID: 25846320.

D’Agostino A, English C, Rey JA. Vortioxetine (Brintellix®): A new serotonergic anti-depressant. P&T 2015, 40 (1):36-40, PMID: 25628505.

Jessica FarrellToledo A, Shapiro L, Farrell J, Magro C, Polito J. Laparos-copy shows superiority over endoscopy for early detec-tion of malignant atrophic papulosis gastrointestinal complications: A case report and review of literature. BMC Gastroenterology, 2015, 15(1), PMID: 26527039.

Robert HamiltonSaroka R, Kane M, Busch R, Watsky J, Hamilton R. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM. Endocrine Practice, 2015, PMID: 26307900.

Nicole LodiseStone RH, Lodise NM, Morin AK, et al. What is the restric-tion on over-the-counter emergency contraception access today? Journal of Adolescent Health 2014; 55(1).

Amy Barton PaiPai AB. Keeping kidneys safe: The pharmacist’s role in NSAID avoidance in high-risk patients. Journal of the American Pharma-cists Association, Jan 1 2015, 55(1):e15-25, PMID: 25503987.

Pai AB. Evaluating plasma pharmacokinetics of IV iron formulations: Judging books by their covers? Clinical Pharmacokinetics, 2015, 54(4):323-4, PMID: 25445844.

Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S, On behalf of the American Society of Nephrology Dialysis Advi-sory Group. Considerations and challenges in defining the optimal utilization of iron in dialysis-dependent chronic kidney disease. Invited Commentary, Journal of the American Society of Nephrology, 2015, 26(6):1238-1247, PMID: 25542967.

Joanna SchwartzJi Y, Schwartz J, Hartford A, Ramsey J, Phillips J, Verschraegen C. Successful treatment of non–small cell lung cancer with erlotinib throughout pregnancy. JAMA Oncology, 2015, 1(6):838, PMID: 26181671.

See-Won SeoGleason SE, Covvey JR, Abrons JP, Dang Y, Seo S, Tofade T, Prescott GM, Peron EP, Masilamani S, Alshari NZ. Connect- ing global/international pharmacy education to the CAPE 2013 outcomes: A report from the global pharmacy education special interest group. 56 p. AACP Center for


the Advancement of Pharmacy Education, Alexandria, VA.

BOOKS

Robert DiCenzoDiCenzo, R., Ed (2015). Clinical Pharmacist’s Guide to Biostatistics and Literature Evaluation: Second Edition. Lenexa, KS: American College of Clinical Pharmacy.

BOOK CHAPTERS

Michael BrodeurBrodeur MR. “Geriatric Disorders” in Fundamentals of Geriatric Pharmacothera-py: An Evidence Based Ap-proach. Hutchinson Sleeper, ed., 2nd Edition, 2015.

Taggart A, Estus E, Boumeester C, Emptage R, Lee J, Mahan R, Slattum PW, Vouri SM, Brodeur MR, Niehoff KM. Geriatric Pharmacy Curriculum Guide, 3rd Edition 2015. American Society of Consultant Pharmacists, 2015.

Brian CowlesCowles B. “Preventing medication errors and harm in children” in Ferri’s Clinical Advisor: Instant Diagnosis and Treatment. Ferri FF, editor, Philadelphia: Mosby Elsevier, 2015, e896.

Robert DiCenzo DiCenzo R. “Biostatistics” in Pediatric Pharmacy Preparatory Review Course (pp. 21-28). Lenexa, KS, American College of Clinical Pharmacy, 2015.

DiCenzo R. Biostatistics. Fundamentals of Bisosta-tistics and Clinical Trial Design. Updates in Thera-peutics (pp. 5-50). Lenexa, KS, American College of Clinical Pharmacy, 2015.

Jessica FarrellFarrell JF, Kennedy AG. “Psoriatic Arthritis” in Ambulatory Care Self- Assessment Program (ACSAP), 2016 Book 1, Endocrinologic/Rheumato-logic Care. Dong BJ, Elliott DP, eds., Lenexa,

KS, American College of Clinical Pharmacy.

Darren GrabeGrabe DW, Cardone KE. “Altered pharmacology and pill burden in the elderly: A balancing act” in Handbook of Dialysis in the Elderly, M. Misra (Ed.), Philadelphia, PA, Springer Healthcare LLC.

Grabe DW. “Hypertension Management” in Nephrol-ogy pharmacotherapy: A pharmacist’s guide to ad-vanced kidney disease and medication management, J. Hudson & D. Mason (Eds).

Michael KaneKane MP. “Hyperthyroid-ism: Graves’ Disease” in Pharmacotherapy Principles and Practice Study Guide: A Case Based Care Plan Approach, 4th Edition. Katz M, Matthias KR, Chisholm-Burns MA, eds., New York, NY, McGraw Hill, 2015.

Kane MP. “Endocrine Disorders” in Updates in Therapeutics®: Ambulatory Care Pharmacy Preparatory Review and Recertifica-tion Course 2015 ed (pp 1-39- 1-96). Bainbridge JL, Branham, A, Coyle EA, et al, eds., Lenexa, KS, American College of Clinical Pharma-cy, 2015.

Nicole LodiseLodise NM, Sutton E. “Sexu-al Dysfunction” in American College of Clinical Phar-macy - Ambulatory Care Self-Assessment Program (ACCP- ACSAP) 2015 Book 2 (Women’s and Men’s Care).

Patrick Meek Meek PD, Brodeur MR. “Palliative medicine issues- constipation/diarrhea” in The Art and Science of Palliative Medicine. Smith H, ed., 2015.

Amy Barton PaiPai AB, Wegrzyn N. “Acute Kidney Diseases” in Drug-Induced Diseases, Prevention, Detection and Management, 3rd

edition. Tisdale J, Miller D, eds., 2015 American Society of Health-systems Pharmacists, Bethesda, MD, 2015.

Pai AB. “Disorders of Calcium and Phosphorus Homeostasis” in Pharmaco-therapy: A Pathophysiologic Approach, Tenth Edition. DiPiro J et al eds., Mcgraw Hill, 2015.

Pai AB. “Iron Oxide Nanoparticles for Treatment of Anemia of Chronic Kid-ney Disease: Too Much of a Good Thing?” in Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety and Risk. R. Bawa (Editor), G. F. Audette and B. E. Reese. (Assistant Editors), Pan Stanford Publishing, Singapore [ISBN 978-981-4669-22-1] 2015.

John PolimeniPolimeni J, Mayumi K. “The Reality of Nuclear Power: Reflections After Fukushima” in The Oxford Handbook of the Macroeconomics of Global Warming. W. Semmler and L. Bernard, eds., Oxford University Press, 2015.

Sarah ScarpaceScarpace, SL. “Oncology” in Updates in Therapeu-tics®: The Ambulatory Care Pharmacy Preparatory Review and Recertification Course, 2015 ed., Volume 1. Bainbridge JL, Branham A, Coyle EA, et al, eds., pp 415-549, Lenexa, KS, Amer-ican College of Clinical Pharmacy, 2015.

Scarpace, SL. “Supportive Care in Oncology” (Chapter 99) in Pharmacotherapy: Principles and Practice, 4th ed. Chisoholm-Burns M, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, and DiPiro JT eds., New York: McGraw-Hill 2015 (In Press).

Emily SuttonLodise NM, Sutton E. “Sexu-al Dysfunction” in American College of Clinical Phar-macy - Ambulatory Care

Self-Assessment Program (ACCP- ACSAP) 2015 Book 2 (Women’s and Men’s Care).

CONFERENCEPRESENTATIONS

SCIENTIFIC POSTERS

Monique BidellPolnak JF, Kennicutt J, Bidell MR. Appropriateness of empiric antibiotic pre-scribing practices for hospi-talized patients with urinary tract infections. American Society of Health-System Pharmacists Midyear Clini-cal Meeting, New Orleans, LA, December 2015.

Laurie BricelandBriceland LL, Kane T, Jab-lanski C. Analysis of ‘Habits of Mind’ cultivated via curricular threading through skills labs and APPEs. American Association of Colleges of Pharmacy (AACP) Annual Meeting Abstract, National Harbor, MD, July 2015.

Scarpace SL, Briceland LL, Feinberg D. Pharmacist in Training (PhiT) portfolio. AACP Annual Meeting School Poster Abstract, Na-tional Harbor, MD, July 2015.

Cai W, Zheng H, DiLorenzo J, Briceland LL, Hao A. A China-US exchange pro-gram for clinical pharmacy experiential education: A 6-year report. AACP Annual Meeting Abstract, National Harbor, MD, July 2015.

Michael BrodeurBlaszczyk A, Estus E, Bouw-meester C, Emptage R, Lee J, Mahan R, Slattum P, Vouri S, Brodeur M, Niehoff K. Developing a geriatric phar-macy curriculum guide, 3rd edition. American Society of Consultant Pharmacists Annual Meeting, Las Vegas, NV, November 2015.

Blaszczyk A, Estus E, Bouwmeester C, Lee J, Mahan R, Brodeur M, Niehoff K. Using the new ASCP geriatric pharmacy curriculum guide: A brand new approach to seeking

professional competency in geriatrics. American Society of Consultant Pharmacist Annual Meeting, Las Vegas, NV, October 31, 2015.

Blaszczyk A., Estus E., Bouwmeester C., Emptage R., Lee J., Mahan R., Slattum P., Vouri S., Brodeur M., Niehoff K. Developing a Geriatric Pharmacy Cur-riculum Guide, 3rd Edition. American Geriatrics Society Annual Meeting, National Harbor, MD, May 2015.

Jeffrey BrewerStrang A, Brewer J, Lubowski T, Brodeur M, Sutton E, Seo S. Assessment of an instructional design change: Peer-led vs Faculty-led SOAP note instruction. Amer-ican Association of Colleges of Pharmacy (AACP) Annual Meeting, National Harbor, MD, July, 2015.

Jo CarrenoCarreno JJ, Sutton E, Schulz K, DiCenzo R. Quarterly variation in respiratory fluo-roquinolone and macrolide prescribing among outpa-tient Medicaid enrollees in Vermont, 2004 - 2014. ICAAC/ICC 2015, San Diego, CA, September 2015.

Jennifer CerulliGeorge J, Houser K, Roberts A, Cerulli J. Development of a quality assurance process to maximize targeted intervention opportunities in a supermarket pharmacy chain. APhA Annual Meet-ing, San Diego, CA, March 2015.

Debra FeinbergFeinberg DF, Lubowski T, Sidlauskas K. Assessing Health and Wellness (HW) IPPE utilizing rubric grading of student projects and reflection summaries. Amer-ican Association of Colleges of Pharmacy (AACP) Annual Meeting Abstract, National Harbor, MD, July 2015.

Michael KaneStryker M, Kane MP, Busch RS, Hamilton RA. Evaluating the off-label use


of once-weekly exenatide in combination with basal insulin therapy in patients with type 2 diabetes melli-tus (Poster #388595). ASHP Midyear Clinical Meeting, New Orleans, Louisiana, December 9, 2015.

Thomas LodiseLodise TP, Ye M, Zhao Q. Relationship between cu-mulative number of prior an-tibiotic exposures and car-bapenem resistance among patients with hospital-onset infections due to enterobac-teriaceae spp (Abstract # 1793). IDWeek2015: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS, San Diego, CA, October 7-11, 2015. Presenter: Lodise.

Bhagnani T, Lodise TP, Wang R, Bhurke S, Zhao Q, Berger A. Patterns of empiric antibiotic therapy among hospitalized patients with complicated intra-abdominal infections or complicated urinary tract infections due to enterobacteriaceae (Ab-stract # 160). IDWeek2015: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS, San Diego, CA, October 7-11, 2015. Presenter: Lodise.

Wang R, Lodise TP, Bhag-nani T, Zhao Q, Bhurke S, Berger A. Clinical and economic burden of hospitalized patients with serious infections due to Carbapenem Resistant Enterobacteriaceae (Ab-stract # 1835). IDWeek2015: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS, San Diego, CA, October 7-11, 2015. Presenter: Zhao.

Mckinnell JA, Griffin M, Humphries R, Hindler J, Crowley O, Bedassie S, Stephenson K, Garland C, Lodise TP. Distribution of Gram-Negative (GN) patho-gens and CarbapenemResistance (CR) patterns across United States hospi-tals: Will klebsiella become the new pseudomonas? (Ab-stract # 1788). IDWeek2015: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS,

San Diego, CA, October 7-11, 2015. Presenter: Mckinnell.

Berger A, Wang R, Zhao Q, Bhagnani T, Bhurke S, Lodise T. Length of stay in hospital associated with empiric use of antibiotics with microbiologic activity against Carbapenem-

Resistant Enterobacteria-ceae (Abstract # S-1347). Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infec-tion (ICC) Joint Meeting, San Diego, CA, September 17-21, 2015. Presenter: Lodise.

Bhurke S, Lodise T, Bhagnani T, Zhao Q, Wang R, Berger A. Costs to treat serious infections due to Carbapen-em-resistant Enterobacteri-aceae in United States (US) hospitals (Abstract # S-1337). Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) Joint Meeting, San Diego, CA, September 17-21, 2015. Presenter: Berger.

Rhodes NJ, Prozialeck W, Lodise T, Venkatesan N, O’Donnell JN, Pais G, Lamar P, Gulati A, Kamilar JM, Scheetz M. Vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury (Abstract # A-977). Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infec-tion (ICC) Joint Meeting, San Diego, CA, September 17-21, 2015. Presenter: Rhodes.

Lodise TP, Travers KU, Martin AL, Ashaye AO, Zhao Q, Dixit S. Association between inappropriate em-piric treatment or delayed appropriate treatment and health outcomes among patients hospitalized with infections due to Klebsiella pneumoniae: How long is too long? (Abstract # 7107).

SHEA Spring Conference, Orlando, FL, May 14-17, 2015. Presenter: Lodise.

Lodise TP, Ye M, Dixit S, Zhao Q. Prevalence of invasive Gram-negative Infections due toCarbapenem-resistant Enterobacteriaceae among adult patients in US inten-sive care units (Abstract # 7121). SHEA Spring Confer-ence, Orlando, FL, May 14-17, 2015. Presenter: Lodise.

Darius MasonCichewicz A, Mason DL, Hudgen E, Gallagher J, El-Fawal HA. Association of Neuroantibodies (NAB) with Glutathione-S-Trans-ferase (GST) Isozyme Polymorphisms (SNP) in African-American children with heavy metal exposure. 54th Annual Meeting of the Society of Toxicology, San Diego, CA, March 2015.

Phelps KR, Mason DL, Kang S. Attributes of the Walton-Bijvoet nomogram at normal and reduced GFR. American Society of Nephrology Renal Week, San Diego, CA, Fall 2015.

Phelps KR, Mason DL. An investigation of the inverse relationship between FEP and TmP/GFR. American Society of Nephrology Renal Week, San Diego, CA, Fall 2015.

Phelps KR, Mason DL, Kang S. FEP misrepresents effects of PTH and FGF23 on P reabsorption in CKD. Amer-ican Society of Nephrology Renal Week, San Diego, CA, Fall 2015.

Patrick MeekMeek PD, Parker WM, Racz MJ, Cosler LE, Teynor ME. Differentiating oral mesal-amine adherence patterns in ulcerative colitis patients: A group-based trajectory model approach. Advances in Inflammatory Bowel Diseases: Crohn’s & Colitis Foundation’s Clinical and Research Conference, Or-lando, FL, December 2015.

Pavilack M, Meek PD. Medication adherence in patients with inflammatory bowel disease: A review of the literature. Academy of Managed Care Pharmacy Annual Meeting & Expo, San Diego, CA, April 2015.

Hwang YN, Meek PD. As-sociation of mental health comorbidity with analgesic prescribing behaviors in the emergency depart-ment setting. Academy of Managed Care Pharmacy: NEXUS Meeting, Orlando, FL, October 2015.

Amy Barton PaiRaouf M, Kelsey T, Wilming C, Cabral K, LaFleur C, Pai AB. A student pharma-cist-led public health initiative for early identi-fication of cardiovascular and kidney disease risk factors. American College of Clinical Pharmacy Global Conference, San Francisco, CA, October 19, 2015.

Pai AB, Meyer D, Bales B, Cotero V, Pai A, Zheng N, Jiang W. Labile iron release from intravenous (IV) iron formulations: Consider-ations for bioequivalence. National Kidney Foundation Spring Clinical Meeting, Dallas, TX, March 27, 2015.

Pai AB, Cardone K, Daoui R, Salenger P, Chen X, Kao T, Boverman G, Davenport D. Utility of bioelectrical im-pedance spectroscopy (BIS) with electrical impedance tomography (EIT) to evaluate regional volume flux in hemodialysis (HD) patients. National Kidney Foundation Spring Clinical Meeting, Dallas, TX, March 27, 2015.

Pai AB, Narsipur S, Gold-stein L. Lipoteichoic acid as a non-invasive marker of biofilm burden in hemodial-ysis (HD) patients. National Kidney Foundation Spring Clinical Meeting, Dallas, TX, March 27, 2015.

Nimish PatelBritt NS, Potter EM, Patel N, Steed ME. Association be-

tween time to treatment and clinical outcomes in vanco-mycin-resistant enterococ-cal bloodstream infection (Abstract #2570). 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 2015. Jakeman B, Nasiri M, Ruth L, Morse C, Mahatme S, Patel N (Abstract #H780; Presenter: Patel). 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 2015.

Sarah ScarpaceAzar D, Scarpace SL. Factors that influence time to start oral chemotherapy. Amer-ican Society of Health-sys-tems Pharmacy (ASHP) Midyear meeting, resident poster session, Session ID 387240, December 6, 2015, New Orleans, LA.

Scarpace SL, Briceland LL, Feinberg D. Pharmacist in Training (PhiT) portfolio. AACP Annual Meeting School Poster Abstract, National Harbor, MD, July 2015.

Joanna SchwartzJi Y, Schwartz J, Verschrae-gen C. The treatment of lung cancer during pregnancy. Annual Meeting of the North-ern New England Chapter of the American Society of Clinical Oncology, Bretton Woods, NY, October 2015.

Kimberly SkylstadGarren T, Skylstad K. Differentiated and flexible learning environment for calculations in a pharmacy skills lab. Northeastern Educational Research Asso-ciation Annual Conference, Trumbull, CT, October 2015.

See-Won SeoStrang AF, Brewer J, Lubowski T, Brodeur M, Sutton E, Seo S. Assessment of an instructional design change: Peer-led vs. Facul-ty-led SOAP note instruction. Midyear Meeting of the American Association of Col-


leges of Pharmacy, National Harbor, MD, July 2015.

Aimee StrangStrang AF, Brewer JM, Lubowski TJ, Brodeur MR, Sutton E. Assessment of an instructional design change: Peer-led vs Faculty led SOAP note instruction. AACP Midyear Meeting, National Harbor, MD, July 2015.

Emily SuttonSutton E, Strang AF, Brewer J, Lubowski T, et al. Assess-ment of an instructional design change: Peer-led vs. Faculty-led SOAP note instruction. Midyear Meeting of the American Association of Colleges of Pharmacy, National Harbor, MD, July 2015.

INVITED PRESENTATIONS

Michael BiddleImmunizations Update. ACPHS Pharmacy Practice Institute, Albany, NY, April 19, 2015.

Biddle MA, Friend C. The Pharmacist’s Role in Rural Communities. Vermont Farm Health Task Force’s Agricultural Medicine Train-ing Course, Burlington, VT, September 23, 2015.

Monique BidellUrinary tract infections: Where are we now? ACPE accredited continuing educa-tion, Albany College of Phar-macy and Health Sciences, Albany, NY, April 2015.

Abby BoireBoire AM, English CD. Com-mon Medication Interac-tions. Invited presentation to the Obstetrics/Gynecology and Family Medicine De-partments at the University of Vermont Medical Center, Burlington, VT, March 2015.

Michael BrodeurMedication Management in Older Adults. Albany Guardian Society, Albany NY, July 2015.

Blaszczyk A, Estus E, Bouwmeester C, Lee J,

Mahan R, Brodeur M, Niehoff K. Using the new ASCP geriatric pharmacy curriculum guide: A brand new approach to seeking professional competency in geriatrics. American Society of Consultant Pharmacist Annual Meeting, Las Vegas, NV, October 31, 2015.

Kate CabralAdvances in Antithrombotic Therapy. Presented for Capital Testing Services LLC, Spring Pharmacy CE Series. Albany, NY and Syracuse, NY. April 2015.

Jo CarrenoInfectious Diseases Update. Pharmacist Society of the State of New York (PSSNY) Mid-Winter Conference, Saratoga Springs, NY, February 2015.

Jennifer CerulliAdvantages of a Health Information Exchange for Pharmacists (1 hour ACPE). Albany College of Pharma-cy and Health Sciences, Albany, NY, April 19, 2015.

Utilizing GOLD Guide-lines to Improve COPD Outcomes (2 hours, ACPE # 0280-0000-15-026-L01-P). PharmEd, Albany, NY, April 30, 2015.

Robert DiCenzoPediatric pharmacy pre-paratory review course: Biostatistics. American Col-lege of Clinical Pharmacy - Updates in Therapeutics. Rosemont, IL, April 10, 2015.

Fundamentals of biostatis-tics and clinical trial design. American College of Clini-cal Pharmacy - Updates in Therapeutics. Rosemont, IL, April 10-14, 2015.

Giselle D’EpiroThe Skinny on Weight Loss Treatment. Vermont Society of Health Systems Phar-macy Spring Conference, Burlington, VT, April 2015.

New Drug Update: Focus on Weight Loss and Insomnia Family Medicine Review

Course. Burlington, VT, June 2015.

Clayton EnglishThe pharmacy perspec-tive: How providers might counsel patients on medical marijuana. Continuing Education presentation at the Alden March Bioethics Institute Clinical Ethics Conference, Albany, NY, November 2015.

Management of neuro-psychiatric symptoms associated with Alzheimer’s Disease. Continuing Educa-tion presentation at Albany College of Pharmacy and Health Sciences, Colches-ter, VT, October 2015.

Personalized precepting: Strategies for teaching students and residents at different levels within phar-macy practice. Continuing Education presentation at Albany College of Pharma-cy and Health Sciences, Albany, NY, August 2015.

Jessica FarrellThe Role of Biologic Therapy in the Management of Rheumatoid Arthritis.10th Annual Clinical Phar-macy Week Conference, Vienna, Austria, September 14, 2015.

The Role of Biologic Ther-apy in the Management of Psoriatic Arthritis.

10th Annual Clinical Phar-macy Week Conference, Vienna, Austria, September 14, 2015.

Case Workshop: A Focus on Biologics in Rheumatoid Ar-thritis. 10th Annual Clinical Pharmacy Week Confer-ence, Vienna, Austria, September 14, 2015.New Biologic Therapies: A Focus on Novel Targets and Cost-Effectiveness. 10th Annual Clinical Pharmacy Week Conference, Vienna, Austria, September 15, 2015.

Biologics: Challenges, Lim-itations, and the Future. 10th Annual Clinical Pharmacy

Week Conference, Vienna, Austria, September 15, 2015.

What’s the Latest Breaking in Rheumatoid Arthritis? American College of Rheu-matology Annual Scientific Meeting - Association of Rheumatology Health Professionals Pre-Meeting Course, San Francisco, CA, November 7, 2015.

Pharmacotherapy: What’s New in Rheumatology? American College of Rheu-matology Annual Scientific Meeting, San Francisco, CA, November 10, 2015.

Updates in pharmacother-apy: A focus on rheuma-toid arthritis and psoriatic arthritis.

Presented to rheumatolo-gists, rheumatology health professionals, and pharma-cy students at the Center for Rheumatology. Albany, NY, November 17, 2015.

Elizabeth HigdonBlood Glucose Monitoring Workshop (1 contact hour CE). Vermont Pharmacists Association (VPA) Spring Meeting, Montpelier, VT, May 2015.

Higdon ER. Diabetes Devic-es. University of Vermont Medical Center, Burlington, VT, December 2015.

Michael Kane Diabetes Update. Central New York Chapter of the New York State Council of Health-system Pharmacists, Syracuse, NY, November 18, 2015.

Effective strategies to re-duce adverse drug events: Prevention of hypoglycemia in the elderly. New York State Chapter of the Amer-ican College of Clinical Pharmacy’s Fall Clinical Meeting, Albany, NY, No-vember 13, 2015.

Diabetes medications: Guidelines for use in the older adult. Upstate New York American Diabetes

Association’s Diabetes Sum-mit - Diabetes and the Older Adult, Scotia, NY, November 4, 2015.

GLP-1 Agonists, SGLT-2 inhibitors and New Insulins: An Update in the Management of Diabetes. Vermont Pharmacists Asso-ciation, Montpelier, VT, May 31, 2015.

GLP-1 Agonists, SGLT-2 inhibitors and “I did inhale”: An Update in the Manage-ment of Diabetes. ACPHS Pharmacy Practice Institute, Albany, NY, April 19, 2015.

Updates In Therapeutics: The Ambulatory Care Phar-macy Preparatory Review Course; Other Endocrine Disorders. Presented Endocrine Disorders section of the Ambulatory Care Pharmacy Preparatory Review Course, ACCP Annual Meeting, Rosemont, IL, April 10, 2015.

Nicole LodiseA Pragmatic and Practical Guide to Get People to Stop Smoking. Outpatient Management of the BIG 7 in our Changing Healthcare Environment: Optimizing Care Using ACO’s/Medical Homes and Minimizing Readmissions, Troy, NY, March 2015.

Women’s Health in the News (1.5 hour CE program). Barbara M. DiLascia Women’s and Men’s Health Symposium, Albany College of Pharmacy and Health Sciences, Albany, NY, October 2015.

Tobacco Cessation: Tips to assist your patient in quitting (1.5 hour CE pro-gram). Vermont Pharmacists Association Fall Meeting, Colchester, VT, October 2015.

Thomas LodiseNew Antimicrobial Update. New York State Chapter of the American College of Clinical Pharmacy Fall Clinical Meeting, November


13, 2015, Albany, NY.Treatment of MRSA blood-stream infections in the 21st century. Infectious Diseases Monthly Meeting, November 5, 2015, Calgary, ALB.

Approaches to drug dose optimization. IDWeek2015: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. Session Title: Antimicrobial Advances that Will Change Your Practice. Session Type: Symposium. October 8, 2015, San Diego, CA.

Antimicrobial Advances that Will Change Your Practice: Gram-Negatives. IDWeek2015: A Joint Meet-ing of IDSA, SHEA, HIVMA, and PIDS. Session Title: An-timicrobial Advances that Will Change Your Practice. Session Type: Symposium. October 8, 2015, San Diego, CA.

Vancomycin PK/PD Efficacy. American College of Clini-cal Pharmacology. Session Title: Vancomycin: Is There Anything Left to Know? Session Type: Symposia. September 27, 2015, San Francisco, CA.

Pharmacodynamic profiling of antibiotics in patients with lower respiratory tract infections. Inter-science Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infec-tion (ICC) Joint Meeting. Session Title: Pharmaco-kinetics/Pharmacodynam-ics (PK/PD) of the Lung. Session Type: Workshop. September 17, 2015, San Diego, CA.

All the things you were told about antibiotic dosing over the years that were wrong. University of Florida School of Pharmacy, August 7, 2015, Gainesville, FL. Quantifying antibiotic ex-posure-effect relationships in patients with infections: A focus on beta-lactams and vancomycin. Institute for Therapeutic Innovation

within the Department of Medicine at the University of Florida, Orlando, FL, August 6, 2015.

Dose optimization op-portunities in critically ill patients. Symposium by the Infectious Disease Association of California (IDAC), in association with the California Department of Public Health entitled, “Practical Antimicrobial Stewardship: Implemen-tation and Expansion in Healthcare Facilities,” July 17, 2015, Irvine, CA.

Advanced Pharmacokinet-ics/Pharmacodynamics. ACPE accredited continuing education, New York State Council of Health-system Antimicrobial Stewardship Program, Hosted by Greater New York Hospital Associa-tion, July 29-30, 2015, New York, NY.

Combination therapy for serious gram-negative infections. ACPE accredit-ed continuing education, New York State Council of Health-system Antimicrobial Stewardship Program, Host-ed by Greater New York Hospital Association, July 29-30, 2015, New York, NY.

New antimicrobial update. Infectious diseases grand rounds at Stratton Veterans’ Affairs Medical Center, June 25, 2015, Albany, NY.

Advanced pharmacokinet-ics/pharmacodynamics. ACPE accredited continuing Education, New York State Council of Health-system Antimicrobial Stewardship Program, Hosted by Greater New York Hospital Associ-ation, May 18-19, 2015, New York, NY.

Combination therapy for serious gram-negative infections. ACPE accredit-ed continuing education, New York State Council of Health-system Antimicrobial Stewardship Program, Host-ed by Greater New York Hospital Association, May

18-19, 2015, New York, NY.Combination therapy for serious gram-negative infec-tions: “Myth or Reality”. 33rd Annual UC Davis Health System Infectious Diseases Conference, February 6, 2015, Sacramento, CA.

New antimicrobial update. ACPE accredited continuing education, Albany College of Pharmacy and Health Sciences, February 8, 2015, Albany, NY.

Amy Barton Pai Biosimilars and non-biologic complex drugs: Current issues. Northeast Kidney Foundation Kidney Care Conference, Excelsior Springs, Saratoga, NY, November 1, 2015.

Are we reaching our full potential in CKD care? Medication management services in CKD. National Institutes of Health, Kidney Interagency Coordinating Committee, Bethesda, MD, September 25, 2015.

Pharmacist-led programs to improve medication safety in kidney disease. 4ª Jornada Integrada de Qualidade em Hemodiálise – Programação, São Paulo, Brazil, June 19, 2015.

Lipoteichoic acid: Potential as a non-invasive marker of biofilm burden. University of São Paulo, Department of Pharmaceutical Sciences, São Paulo, Brazil, June 19, 2015.

Clinical challenges with IV iron use in kidney disease. GDUFA FY 2015 Regulato-ry Science Initiatives Part 15 Public Meeting, Silver Spring, MD, June 5, 2015.

Top ten reasons to have a pharmacist of the ESKD team. National Kidney Foundation Spring Clinical Meeting, Dallas, TX, March 25, 2015.

Top ten nephrotoxic drugs. National Kidney Foundation Spring Clinical Meeting,

Dallas, TX, March 26, 2015.Generic IV iron formulations: Black solutions in a regu-latory gray area. National Kidney Foundation Spring Clinical Meeting, Dallas, TX, March 28, 2015.

Amit PaiChallenges of dosing antimicrobial in obesity. Expert Panel on Obesity and Infection, Chicago, IL, November 2015.

Daptomycin dosing in criti-cally ill patients. Infectious Diseases Conference, University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, ONT, October 2015.

Dosing strategies for obese patients in the ICU. Infec-tious Diseases Conference, University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, ONT, October 2015.

Vancomycin dosing in obesity: Is body weight the best descriptor? Annual Meeting of the American College of Clinical Pharma-cology, San Francisco, CA, September 2015.

Pai MP, Hope W. (Conve-ners) I have a white powder but want a drug: Shepherd-ing compounds through the Valley of Death, San Diego, CA, September 2015.

Antimicrobial dosing consid-erations in obese patients with chronic kidney disease. CINE-HDC-Renal Class and University of Sao Paulo, Integrated Quality Sympo-sium on Hemodialysis, Sao Paulo, Brazil, June 2015.

Finding the right dose and schedule to optimize antimi-crobials. Argentine Society of Infectious Diseases An-nual Meeting, Buenos Aires, Argentina, June 2015.

Treatment of resistant gram-positive bacteria: A pharmacologic perspec-tive. Argentine Society of Infectious Diseases Annual Meeting, Buenos Aires, Argentina, June 2015.

Dosing regimen matters. Continuing Education, Visiting Professorship, Uni-versity of Illinois at Chicago, Chicago, IL, April 2015.

Antimicrobial dosing reg-imen matters. Continuing Education, Annual Infectious Diseases Program, Albany College of Pharmacy and Health Sciences, Albany, NY, February 2015.

Nimish PatelHIV resistance overview for providers – 2015. ACPE accredited continuing edu-cation telemedicine series broadcast to all New York State Department of Correc-tions pharmacists. Albany Medical Center HIV Clinic, Albany, NY, February 2015.

HCV Update 2015. Grand rounds to physicians at Nathan Littaeur Hospital, Gloversville, NY, February 2015.

What’s new in HCV pharma-cotherapy. ACPE accredited continuing education, Al-bany College of Pharmacy and Health Sciences, Alba-ny, NY, February 2015.

Sarah ScarpaceHPV positive oropharyngeal cancer: Is it time to de-es-calate therapy? 30-minute ACPE-accredited program presented to pharmacists at the American College of Clinical Pharmacy Annual Meeting. San Francisco, CA, October 19, 2015.

Practical issues with new targeted therapies for cancer. 1-hour ACPE-accred-ited program presented to pharmacists as part of the Association of Community Cancer Centers (ACCC) On-cology Pharmacy Education Network (OPEN) conference. Charlotte, NC, July 10, 2015 / Fort Lauderdale, FL, June 26, 2015 / New Brunswick, NJ, May 15, 2015.

Hematology/Oncology. 1-hour ACPE-accredited program presented to pharmacists as part of the


D E P A R T M E N T O F P H A R M A C E U T I C A L S C I E N C E S – A L B A N Y C A M P U S

PUBLICATIONS


Hassan El-FawalAl-sofiani M, Aljammah A, Hasanato A, Racz M,

Mason D, El-Fawal HAN, Mousa SA. Effect of vitamin D supplementa-tion on glucose control and inflammatory response in type 2 diabetes: Double blind, randomized clinical

trial. International Journal of Endocrinology Metabolism, Jan 2015, 13(1):e22604, doi: 10.5812/ijem.22604.

Yasin BR, El-Fawal HAN, Mousa SA. Date (phoenix

dactylifera) polypheno-lics and other bioactive compounds: A traditional Islamic remedy’s potential in prevention of cell damage, cancer ther-apeutics and beyond.

International Journal of Molecular Sciences, 2015, 17;16(12):30075-90. doi: 10.3390/ijms161226210.

Carlos FelederJohnson A, Neumann PH,

American College of Clinical Pharmacy (ACCP) Updates in Therapeutics 2015: Ambulatory Care Pharmacy Preparatory Review and Recertification Course. Chi-cago, IL, April 11, 2015.

Sivik J, Iacovelli L, Scarpace SL, Parsons K. Practice pan-el: Survivorship. 20-minute presentation as part of a 1.5-hour ACPE-accredited panel discussion presented to pharmacists at the Hema-tology/Oncology Pharmacy Association (HOPA) 11th Annual Meeting. Austin, TX, March 26, 2015.

Oncology new drug update. 1.5-hour ACPE-accredited CE program presented to pharmacists at the Capital Testing Services Pharmacy Clinical Practice and Law Update program. Holiday Inn Airport, Buffalo, NY, April 17, 2015; Holiday Inn Airport, Rochester, NY, April 18, 2015; Holiday Inn Express, Latham, NY, April 10, 2015.

Joanna SchwartzHerbal interactions with che-motherapy. Vermont Breast Cancer Symposium, Burling-ton, VT, October 2015.

See-Won SeoNew Drug Update. ACPE accredited continuing education, Pharmacists Society of the State of New York, Saratoga Springs, NY, January 2016.

Aimee StrangDesign, development, and implementation of a multi-campus online gradu-ate elective for health pro-

fessionals. Conference on Higher Education Pedagogy, Blacksburg, VA, Feb 2015.

Emily SuttonAcute and long term complications of diabetes. Presentation to Vermont Pharmacy Association, Montpelier, VT, 2015.

EXTRAMURALGRANTS

Jo Carreno Project: Impact of a Multidis-ciplinary Team on Time to Sepsis ResolutionGrantor: ASHP Research and Education FoundationAmount: $75,000Term: 5/1/15 - 10/31/16

Amy Barton PaiProject: A community based study of adverse effects of NSAIDs on the kidney and risk mitigation to reduce preventable harmGrantor: Food and Drug AdministrationGrant No.: BAA-15-00121Amount: $203,733 Term: 9/30/15 - 7/31/17

Amit PaiProject: Single Dose Phar-macokinetics of Intravenous Tedizolid Phosphate in Morbidly Obese and Age-, Sex-, and Ideal Body Weight-Matched Non-Obese Adults Grantor: Merck, Inc. Amount: $179,824Term: 1/28/15 - until complete

Nimish PatelProject: Prevalence of Contraindicated Drug-Drug Interactions between Sofos-buvir/Ledipasvir and Ombit-asvir/Dasabuvir/ABT450/Ri-

tonavir +/- Ribavirin among Patients Coinfected with Human Immunodeficiency Virus and Hepatitis CGrantor: Gilead SciencesAmount: $26,720Term: 4/1/15 - until complete

Project: Prevalence of Contraindicated Drug-Drug Interactions after addition of Sofosbuvir / Ledipasvir and Ombitasvir/Dasabuvir/ABT450/Ritonavir +/- Riba-virin to Medication Profiles of Patients with Chronic Hepatitis C MonoinfectionGrantor: Gilead SciencesAmount: $36,371Term: 4/1/15 - until complete

PROFESSIONAL APPOINTMENTS

Michael A. Biddle. Appoint-ed by Gov. Shumlin to the Vermont Medicaid Drug Utilization Review Board.

Michael R. Brodeur. Ap-pointed by Gov. Cuomo to the New York Justice Center Medical Review Board.

Katherine P. Cabral. Presi-dent-elect of the New York State chapter of the Amer-ican College of Clinical Pharmacy (ACCP).

Andy Flynn. Region 7 Representative of the Phar-macists Society of Sate of New York (PSSNY).

Andy Flynn. Treasurer of the Capital Area Pharmacists Society (CAPS).

Andy Flynn. Member of the Blue Shield of Northeastern New York P&T Committee.

Andy Flynn. Appointed to the Editorial Board of the PSSNY journal New York Pharmacists Century II.

Sarah L. Scarpace. Elected to three year term (2015 - 2018) as President-elect/President/Past-President of the Hematology/Oncology Pharmacy Association (HOPA).

Jennifer Cerulli. American Pharmacists Association Medication Therapy Man-agement (MTM) Evidence Advisory Panel.

Robert DiCenzo. Presi-dent-elect of the APhA Academy of Pharma- ceutical Research and Science.

Clayton English. Appointed by Gov. Shumlin to the Vermont Medicaid Drug Utilization Review Board.

Gina D. Garrison. Executive Council, Rho Chi Pharmacy Honor Society.

Gina D. Garrison. Associate Editor, Currents in Pharmacy Teaching and Learning (term ended in 2015)

Gina D. Garrison. Public Policy Committee Member, New York State Council of Health- system Pharmacists.

Michael P. Kane. Editorial Board Member of Case Reports in Endocrinology.

Michael P. Kane. Northeast Kidney Foundation – Board of Directors, Trustee.

Nicole M. Lodise. Faculty Affairs Workgroup Chair of the American Association of Colleges of Pharmacy (AACP) Council of Faculties - Curricular Adoption and Integration of the Pharma-cists’ Patient Care Process.

Thomas Lodise. Chair, ARLG PK/PD Special Emphasis Panel of Antibiotic Resis-tance Leadership Group (ARLG).

Thomas Lodise. Vancomy-cin consensus guideline committee member of American Society of Health-System Pharma-cists, Infectious Disease Society of America, Society of Infectious Disease Pharmacists, and the Pediatric Infectious Disease Society.

Thomas Lodise. Editorial Board Member of Antimicro-bial Agents and Chemo-therapy.

Thomas Lodise. Editorial Board Member of Pharma-cotherapy.

Thomas Lodise. Editori-al Board of Diagnostic Microbiology and Infectious Diseases.

Darius L. Mason. Chair-Elect of the APhA Academy of Pharmaceutical Research and Science’s Clinical Sciences Section.

Amy Barton Pai. Chair of the Pharmacy Work Group for the NIH-National Kidney Disease Education Program (NKDEP).


Peng J, James J, Russo V, MacDonald H, Gertzberg N, Feleder C.

The intracerebroventricular injection of rimonabant inhibits systemic lipopoly-saccharide-induced lung inflammation. Journal of Neuroimmunology, Sep 15, 2015; 286:16-24.

Millington WR, Yilmaz MS, Feleder C. The initial fall in arterial pressure evoked by endotoxin is mediated by the ventrolat-eral periaqueductal gray. Clinical and Experimen- tal Pharmacology and Physiology (Submitted: In Revision).

Feleder C, Sertac Yilmaz MS, Peng J, Göktalay G, Millington WR. The OVLT initiates the fall in arterial pressure evoked by high dose lipopolysaccharide: Evidence that dichotomous, dose-related mechanisms mediate endotoxic hypoten-sion. Journal of Neuro-immunology, Aug 2015, 285:94-100.

William MillingtonFeleder C, Yilmaz MS, Peng J, Göktalay G, Millington WR. The OVLT initiates the fall in arterial pressure evoked by high dose lipopolysaccharide: Evidence that dichotomous, dose-related mechanisms mediate endotoxic hypotension. Journal of Neuroimmunology, Aug 2015, 285:94-100.

Millington WR, Yilmaz MS, Feleder C. The initial fall in arterial pressure evoked by endotoxin is mediated by the ventrolateral periaque-ductal gray. Clinical and Experimental Pharmacology and Physiology (Submitted: In Revision).

Basaran NF, Buyukuysal LR, Yilmaz, SM Aydin S, Cavun S, Millington WR. The effect of Gly-Gln [ß-endorphine30-31] on morphine-evoked serotonin and GABA efflux in the

nucleus accumbens of con-scious rats. Neuropeptides (In Press).

Göktalay G, Millington WR. Hypovolemic hemorrhage induces Fos expression in the rat hypothalamus: Evidence for involvement of the lateral hypothalamus in the decompensatory phase of hemorrhage. Neurosci-ence (In Press).

Musteata FM, Sandoval M, Ruiz JM, Harrison K, McKenna D, Millington W. Evaluation of in vivo solid phase microextraction for minimally invasive analysis of nonvolatile phytochem-icals in Amazonian plants. Analytica Chimica Acta (In Review).

Marcel Mustata LaPorte B, Musteata FM. Fluidic device for generat-ing pharmacokinetic profiles matching preset param-eters. Journal of Pharma-ceutical Innovation, 10(3), 222-232, 2015.

Donabella P, Rogers N, Levin R, Musteata FM. Development of supported liquid phase microex-traction probes for in vivo pharmacokinetic studies. Bioanalysis, Vol. 7(6), p. 661-670, DOI 10.4155/bio.15.7, 2015.

Alsaqr A, Rasoully M, and Musteata FM. Investigating transdermal delivery of vitamin D3. AAPS Pharm-SciTech, 16(4), DOI 10.1208/s12249-015-0291-3, 2015.

Mason D, Donabella P, Nnani D, Musteata FM. Normalized vitamin D metabolite concentrations are better correlated to pharmacological effects than measured concen-trations. Future Science OA, FSO83 doi: 10.4155/FSO.15.83, 2015.

Musteata FM, Sandoval M, Ruiz JM, Harrison K, McKenna D, Millington WR. Evaluation of in vivo solid phase microextraction for

minimally invasive analysis of nonvolatile phytochem-icals in Amazonian plants. Analytica Chimica Acta (In Review)

HaiAn ZhengZheng HA, Truong J, Carroll F, Pai MP. Do formulation differences between reference listed drug and generic products of piperacillin-tazobactam impact reconstitution? Antimicrobial Agents and Chemotherapy, 59 (3) 1767-1769, 2015.

BOOK CHAPTERS

Hassan El-FawalEl-Fawal, HAN. “Court Systems” in Encyclopedia of Forensic and Legal Medi-cine. Payne-James J, Byard R, Corey T, Henderson C, eds., 2nd Edition, Volume 2, pp. 662–672, Elsevier Pub-lishing, London, UK, 2016.

El-Fawal, HAN. “Judicial Punishment” in Encyclope-dia of Forensic and Legal Medicine. Payne-James J, Byard R, Corey T, Hender-son C, eds., 2nd Edition, Volume 3, pp. 282–290, Elsevier Publishing, London, UK, 2016.

El-Fawal HAN, Rembisz P, Alobaidi R, Mousa, SA. “Chemotherapy-mediated pain and peripheral neu-ropathy: Impact of oxidative stress and inflammation” in Oxidative Damage and Antioxidant Imbalance: The Science of Biology in Health and Disease. Armstrong F, Stratton RD, eds., pp: 367-388, John Wiley & Sons, Inc., 2016.

El-Fawal, HAN. “The Tree and the Forest: A Need for Dialogue and a Collaborative Approach in the Safety of Nanomedi-cines” in Handbook of Clinical Nanomedicine Volume II: Law, Business, Regulation, Safety and Risk. Bawa R (Editor), Audette GF and Reese BE (Assistant Editors), Pan Stanford Publishing, Singapore, 2016.

HaiAn ZhengWu L, Smith H, Zheng HA, Yu L. Drug Product Approval in the United States and International Harmonization, Developing Oral Solid Dosage Forms. Academic Press, in press (book chapter co-author).

Zheng, HA. Intravenous Infusion, Applied Biophar-maceutics and Pharmaco-kinetics, 7th Edition. Leon Shargel and Andrew Yu, eds., McGraw-Hill, Septem-ber 4, 2015 (chapter editor).

CONFERENCE PRESENTATIONS

Richard Dearborn, Jr.Ainsworth M, Voigt JM, Dearborn Jr. RE. Hedge-hog-dependent regula-tion of the VDUP1 tumor suppressor in Drosoph-ila: Developmental and promoter analyses. AAPS Conference, Farmington, CT, April 16, 2015 (abstract).

Hassan El-FawalEl-Fawal HAN. Neurotoxic and autoimmune potential of nanoparticles: Aggrava-tion to amelioration. First International Nanomedicine Symposium and Workshop, ACPHS, August 3-7, 2015.

Cichewicz A, Mason D, Hudgens E, Gallagher JE, El-Fawal HAN. Association of neuroantibodies (NAB) with glutathione-S-trans-ferase (GST) isozyme polymorphisms (SNP) in African-American children with metal exposures. So-ciety of Toxicology Annual Meeting, San Diego, CA, 2015.

Dougherty K, Cichewicz A, Hudgens E, Galla- gher JE, El-Fawal HAN. Neuroantibodies (NAB) in African-American (AA) children with metal exposures associate with cytokine and human leukocyte antigen (HLA) polymorphisms (SNP). Society of Toxicology Annual Meeting, San Diego, CA, 2015.

Sardar J, Mason D, El-Fawal HAN. Association of autoantibodies to nervous system (NS) proteins (NAb) with demographics in hemodialysis (HD) patients. American Association of Pharmaceutical Sciences (AAPS) Regional Meeting, Storrs, CT, 2015.

Monaco-Brown M, Price D, Horgan M, El-Fawal HAN. Translational utility of neuroantibody (NAb) biomarkers in hypoxic-isch-emic encephalopathy (HIE). Eastern Society for Pediatric Research, Philadelphia, PA, 2015.

Monaco-Brown M, Price D, Horgan M, El-Fawal HAN. Translational utility of neuroantibody (NAb) biomarkers in hypoxic-isch-emic encephalopathy (HIE). Pediatric Academic Societ-ies Annual Conference, San Diego, CA, 2015.

Carlos FelderRusso V, Peng J, Mac- Donald H, Neumann P, Gertzberg N, Johnson A, Feleder C (presenter). Brain endocannabinoids mediate lung inflammation during septic shock. Inter-national Brain Research Organization 9th World Congress, Rio de Janeiro, Brazil, 2015.

Feleder C. Brain inflam-mation and psychiatric disorders: Depression and anxiety. Favaloro Univer-sity, School of Medicine, Buenos Aires, Argentina, August 2015.

Feleder C. Brain endocan-nabinoids initiates bacterial hypotension and lung in-flammation during septic shock. Favaloro University, School of Medicine, Buenos Aires, Argentina, August 2015.

Feleder C. Brain endocan-nabinoids initiate bacterial hypotension and lung inflammation during septic shock. University Barcelo, School of Medicine, Buenos


Aires Argentina, August 2015.

Marcel MustataLaPorte B, Musteata FM. Desktop RAT for generating in vitro pharma-cokinetic profiles. Pittcon 2015, New Orleans, LA, March 2015 (oral presen-tation).

LaPorte B, Musteata FM. 4D-Printed Phar-macokinetic Profiles in Teaching and Research. AAPS-NERDG, Farming-ton, CT, April 2015 (poster presentation).

HaiAn ZhengZheng HA. Regulatory Science and Botanical

Drug Products – Quality for Safety. China-America Herbal Safety Symposium, Shanghai, JiaoTong Uni-versity Affiliated Tongren Hospital, October 5, 2015 (invited talk).

Cai W, Zheng HA, DiLoren-zo J, Briceland LL, Hou A. A China-US exchange

program for clinical pharmacy experiential education: A 6-Year Report. AACP Annual Meeting, National Harbor, MD, July 11-14, 2015.

Zheng, HA. Regulatory science for botanicals and biologicals – Something old and something new.

Fudan University School of Pharmacy, June 25, 2015 (invited talk).

Cha W, Park K, Zheng HA. Exploring the binding inter-face between human leptin and leptin receptor. AAPS Northeast Regional Annual Meeting, Hartford, CT, April, 16, 2015.

D E P A R T M E N T O F P H A R M A C E U T I C A L S C I E N C E S – V E R M O N T C A M P U S

PUBLICATIONS


Stefan Balaz Balaz S. Response to “Com-ment on ‘Structural Deter-minants of Drug Partitioning in Surrogates of Phosphati-dylcholine Bilayer Strata.’” Molecular Pharmaceutics 2015, 12, 1330–1334.

Tamer Fandy Fandy TE, Abdullah I, Khayat M, Colby D, Hassan H. In vitro characterization of transport and metabolism of the alkaloids; vincamine, vinpocetine and eburna-monine. Cancer Chemo-therapy & Pharmacology 2016, 77, 259-267 (online Dec 2015).

Hamed AA, Wu X, Erickson R, Fandy TE. Twitter K-H net-works in action: Advancing biomedical literature for drug search. Journal of Bio-medical Informatics 2015, 56, 157-168.

Hassan H, Carlson S, Abdal-lah I, Buttolph T, Glass KC, Fandy TE. Curcumin and dimethoxycurcumin induced epigenetic changes in leu-kemia cells. Pharmaceutical Research 2015, 32, 863-875.

Karen GlassKim S, Natesan S, Corniles-cu G, Carlson S, Tonelli M, McClurg UL, Binda O, Robson CN, Markley JL, Balaz S, Glass KC. Mecha-nism of Histone H3K4me3

recognition by the plant homeodomain of inhibitor of Growth 3. Journal of Biolog-ical Chemistry (in revision).

Yana CenPatel J, Huynh MT, Sowers ML, Theruvathu JA, Zhang K, Sowers LC, Cen Y. Syn-thesis and characterization of pyrimidine 2’-deoxynu-cleoside monophosphates as biomarkers of DNA damage and enzymatic modification, Analytical Biochemistry (accepted).

BOOK CHAPTERS

Tamer FandyFandy TE. “Epigenetic modifications induced by curcumin and its congeners” in Curcumin: Clinical Uses, Health Effects and Potential Complications. Edited by Valeria Martin, Nova Science Publishers, Haup-pauge, NY (in press).


Stefan BalazSTEM Saves Lives and Creates Jobs. Vermont Biosciences Alliance, Burlington, VT, April 13, 2015 (panelist).

Tamer Fandy Fandy TE. Epigenetic modifiers as antitumor agents. Festival of Genomics, Boston, MA, June 22-24, 2015.

Hassan H, Keita JA, Narayan L, Brady S,

Frederick R, Carlson S, Glass KC, Buttolph T, Fandy TE. The interactive effects of dimethoxycurcumin and decitabine in leukemia cells. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Abstract T3011, 2015.

Hassan H, Keita JA, Narayan L, Brady S, Fred-erick R, Carlson S, Glass KC, Buttolph T, Fandy TE. The interactive effects of dimethoxycurcumin and decitabine in leukemia cells. Annual ACPHS Research Forum, Albany, NY, 2015.

Karen GlassCarr F, Glass KC, and Gray J. Epigenetic Signaling and Breast Cancer. Invited talk for panel session on Environmental Endocrine Disruptors and Their Impact on Weight, Metabolism, and Cancer, The 18th Annual Women’s Health and Breast Cancer Conference, Burling-ton, VT, Oct 2, 2015.

Glass KC, Lubula MY, Poplawski A, Carlson S, Eckenroth BE, Hu K, Lee W, Peng D, Chruszcz M, Shi X, Markley JL. Molecular basis of histone acetyllysine recognition by the BRPF1 bromodomain. 5th Annual ACPHS Research Forum, Albany, NY, January 24, 2015.

Carlson S, Lubula MY, Eckenroth BE, Poplawski P, Neuhardt E, Glass KC.

Epigenetic roles of the MOZ histone acetyltransferase complex. Keystone Sym-posia on Epigenetics and Cancer, Keystone, CO, Jan 26, 2015.

Glass KC, Lubula MY, Poplawski A, Carlson S, Eckenroth BE, Hu K, Lee W, Peng D, Chruszcz M, Shi X, Markley JL. Molecular Basis of Histone Acetyllysine Recognition by the BRPF1 Bromodomain. Keystone Symposia on Epigenetics and Cancer, Keystone, CO, Jan 26, 2015.

Glass KC. Molecular basis of histone recognition by the MOZ HAT complex. Epigenomics and Novel Therapeutic Targets, Boston, MA, 2015 (invited talk and session chair of Transcriptional Regulation).

Glass KC. Round Table dis-cussion, Vermont Genetics Network Career Day, Burl-ington, VT, April 15, 2015.

Senthil NatesanNatesan S, Lynch S, Subramaniam R, Mathew I, Wang Z, Balaz S. Frag-ment-based prediction of drug distribution across the headgroup and core strata of a phospholipid bilayer: Hexadecane-dia-cetyl phosphatidylcholine as surrogate phases. 250th American Chemical Society National Meeting, Boston, MA, August 16-20, 2015, COMP-280.

Natesan S, Glass KC, Balaz S. Molecular dynamics simulations of ING3-histone peptides: Free energy calculations and analysis of critical interactions. 5th Annual ACPHS Research Forum, Albany, NY, January 24, 2015.

Petrow B, Natesan S, Cen Y, Balaz S. SIRT6 inhibitors: Lead generation through pharmacophore based virtual screening, molecular docking and molecular dynamics simulation. 5th Annual ACPHS Research Forum, Albany, NY, January 24, 2015.

Yana Cen Cen Y, Zhang K, Lin H. Activity-based photoaffin-ity labeling of sirtuins. 5th Annual ACPHS Research Forum, Albany, NY, January 24, 2015.

Cen Y, Zhang K, Lin H. De-velopment of activity-based chemical probes for sirtuin profiling. Epigenomics and Novel Therapeutic Targets Conference, Boston, MA, May 2015.


S C H O O L O F A R T S A N D S C I E N C E S

D E P A R T M E N T O F B A S I C A N D S O C I A L S C I E N C E S

PUBLICATIONS

Charles BergeronSiedlik JA, Bergeron C, Coo-per MA, Emmons R, Moreau W, Nabhan D, Gallagher P, Vardiman JP. Advanced treatment monitoring for athletes using unsuper-vised modeling techniques. Journal of Athletic Training, in press.

Bergeron C, Lebl J, and other open-source creators. Differential equations: In-cluding linear algebra topics and computer-aided prob-lem-solving. Self-published online at www.differentiale-quations.net, CC BY-NC-SA 3.0 license, Aug 29, 2015.

Allison M. Burton-ChaseHovick SR, Yamasaki J, Burton-Chase AM, Peterson SK. Patterns of family health history communication among African American older adults. Journal of Health Communication, 2015, 20 (1); 80-87.

Yusuf RA, Rogith D, Hovick SR, Peterson SK, Bur-ton-Chase AM, Fellman BM, Li Y, McKinney C, Bernstam EV, Meric-Bernstam F. Attitudes toward molecular testing for personalized cancer therapy. Cancer, 2015, 121 (2); 248-250.

Burton-Chase AM, Swartz MC, Silvera SAN, Basen-En-gquist K, Fletcher FE, Shields PG. Know your value: Ne-gotiation skills development for junior investigators in the academic environment – A report from the American Society of Preventive Oncology’s Junior Members Interest Group. Cancer Epidemiology, Biomarkers & Prevention, 2015, 24 (7); 1144-1148.

Katz LH, Burton-Chase AM, Advani S, Fellman F, Polivka K. Ying Y, Lynch PM, Pande M, Peterson SK. Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome. Clinical Genetics, 2015, Epub ahead of print.

Burton-Chase AM, Kwak J, Hennig K, Haley WE. Elder Caregiving. In Reference Module of Neuroscience and Biobehavioral Psychology. New York: Elsevier, in press.

Timothy LaRoccaLaRocca TJ, Stivison EA, Mal-Sarkar T, Hooven TA, Hod EA, Spitalnik SL, Ratner AJ. CD59 signaling and membrane pores drive Syk-dependent erythrocyte necroptosis. Cell Death and Disease, May 2015, 6: e1773.

Meenakshi MalikSuresh RV, Ma Z, Sunagar R, Bhatty V, Banik S, Catlett SV, Gosselin EJ, Malik M*, Bak-shi CS*. Preclinical testing of a vaccine candidate against tularemia. PLoS One, April 2015, 10(4): e0124326 (* de-notes co-senior authors).

Banik S, Mansour AA, Suresh RV, Wykoff-Clary S, Malik M, McCormick AA, Bakshi CS. Development of a multivalent subunit vac-cine against tularemia using Tobacco Mosaic Virus (TMV) based delivery system. PLoS One, June 2015, 10(6): e0130858.

Rabadi SM, Sanchez BC, Varanat M, Ma Z, Catlett SV, Melendez JA, Malik M*, Bakshi CS*. Antioxidant de-fenses of Francisella tularen-sis modulate macrophage function and production of

proinflammatory cytokines. Journal of Biological Chem-istry, 2015 Dec 7. pii: jbc.M115.681478. [Epub ahead of print] PMID: 26644475 (* denotes co-senior authors).

Thomas O’GradyO’Grady TJ, Gates MA, Boscoe FP. Thyroid cancer incidence attributable to over-diagnosis in the United States 1981-2011. Internation-al Journal of Cancer, Dec 1, 2015, 137(11):2664-73.

Wendy ParkerCampo-Engelstein L, San-tacrose LB, Master Z, Parker WM. Bad moms and blame-less dads: The portrayal of maternal and paternal age and preconception harm in U.S. newspapers. American Journal of Bioethics: Em-pirical Bioethics, 2016, 7(1): 56-63. DOI:10.1080/23294515.2015.1053007.

Parker WM, Cho S, Muzzy JD, Cardone KE. Multidis-ciplinary views toward pharmacist-delivered MTM services in dialysis facilities. Journal of the American Pharmacists Association, 2015, 55 (4): 390-397, doi: 10.1331/JAPhA.2015.14168.

Campo-Engelstein L, How-land L, Parker WM, Burcher P. Scheduling the stork: Me-dia portrayals of women’s and physicians’ reasons for cesarean delivery on ma-ternal request. Birth, 2015, 42:2:181-188.

Michael RaczRacz MJ, Sedransk J. Infer-ence for identifying outlying health care providers. Jour-nal of Statistical Planning and Inference, 2015, 160, 51-59.

Alyahya R, Sudha T, Racz MJ, Stain SC, Mousa SA.

Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight hep-arin in surgical pancreatic cancer models. International Journal of Oncology, 2015, 46, 1225-1231.

Al-Sofiani ME, Jammah A, Racz MJ, Khawaja RA, Hasanto R, El-Fawal HAN, Mousa SA, Mason DL. Effect of vitamin D supplementa-tion on glucose control and inflammatory response in type II diabetes: A double blind, randomized clinical trial. International Journal of Endocrinology and Metabo-lism, 2015, 13(1), e22604. Alzahri M, Almomen A, Hasanato R, Racz MJ, Polimeni J, Mousa SA. Lactate dehydrogenase as a biomarker for early renal damage in patients with sickle cell disease. Saudi Journal of Kidney Diseases and Transplantation, 2015, 26(6):1161-1168.

PRESENTATIONS

Charles BergeronBergeron C, Kiehl TR. Ex-tracting connectivity patterns from neural spikes. Joint Mathematics Meetings, San Antonio, TX, January 10-13, 2015 (oral presentation).

Bergeron C. A flipped dif-ferential equations with no videos. Joint Mathematics Meetings, San Antonio, TX, January 10-13, 2015 (oral presentation).

Stone T, Kiehl TR, Bergeron C. The role of spatial scale in neural tissue interconnec-tivity. Next Generation Stem Cell Conference, Saratoga Springs, NY, May 6-7, 2015 (poster presentation).

Stone T, Kiehl TR, Bergeron C. The role of spatial scale in neural tissue interconnec-tivity. Hitting the Accel-erator: Health Research Innovation through Data Science Scientific Session, Rochester, NY, May 28, 2015 (poster presentation).

Stone T, Kiehl TR, Bergeron C. The role of spatial scale in neural tissue interconnec-tivity. New York Academy of Sciences Quantitative Biology: From Molecules to Man, New York, NY, June 18, 2015 (poster presentation).

Stone T, Kiehl TR, Bergeron C. Learning biological func-tion at various spatial scales in electrophysiological big data. New York Academy of Sciences Leveraging Big Data and Predictive Knowledge to Fight Disease, New York, NY, July 28, 2015 (poster presentation).

Allison M. Burton-ChaseAdvani S, Polivka K, Katz LH, Burton-Chase AM, Fellman F, Ying Y, Lynch PM, Pande M, Peterson SK. Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome. MD Anderson Cancer Sur-vivorship Research Retreat, Houston, TX, February 2015 (poster presentation).

Advani S, Polivka K, Katz LH, Burton-Chase AM, Fellman F, Ying Y, Lynch PM, Pande M, Peterson SK. Cancer risk perceptions and screening behaviors in family members of colorectal cancer survivors with Lynch-like syndrome. MD Anderson Cancer Sur-vivorship Research Retreat, Houston, TX, February 2015 (poster presentation).


Burton-Chase, AM. Creating and managing a work-life balance in the academic environment: Strategies for Junior Investigators. Annual Meeting of the American Society of Preventive On-cology (ASPO), Birmingham, AL, March 2015 (session chair and organizer).

Katz LH, Burton-Chase AM, Advani S, Fellman F, Polivka K, Ying Y, Lynch PM, Pande M, Peterson SK. Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome. Digestive Disease Week (DDW), Washington, DC, May 2015 (oral presentation).

Burton-Chase, AM. Transi-tions in care and provider satisfaction in Lynch syn-drome survivors and previ-vors. 19th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer, Balti-more, MD, October 2015 (invited oral presentation and panelist).

Martha HassMathur S, Thomas S, Hass MA. Synthesis and evalu-ation of co-drugs derived from methotrexate and ibuprofen. American Asso-ciation of Pharmaceutical Scientists Annual Meeting, Orlando, FL, October 25-29, 2015 (poster presentation).

Jock M, Mackey S, Thomas S, Hass MA. Stability and penetration of co-drugs derived from tocopherol (TOC)/tocopherylamine (TOCA) and lipoic acid/lipol in porcine skin. American Association of Pharma- ceutical Scientists Annual Meeting, Orlando, FL, October 25-29, 2015 (poster presentation).

Mathur S, Thomas S, Hass MA. Synthesis of co-drugs derived from methotrexate and ibuprofen. 15th Annual AAPS Northeast Regional Discussion Group, Farm-ington, CT, April 16, 2015 (poster presentation).

Timothy LaRoccaLaRocca, TJ. Mechanisms and significance of necro-ptosis. ACPHS-Wadsworth Center Mini-Research Sym-posium, Albany, NY, June 1, 2015 (oral presentation).

LaRocca TJ, Flaherty NF, Ratner AJ. Hyperglycemic conditions prime cells for RIP1-dependent programmed necrosis in a glycolysis-de-pendent manner. Eastern New York Student Chapter of the American Society for Microbiology (ENYSCASM), Albany, NY, November 4, 2015 (poster presentation).

Meenakshi MalikMalik M. Immunopatho-genesis of Francisella tula-rensis. ACPHS-Wadsworth Center Mini-Research Sym-posium, Albany, NY, June 1, 2015 (oral presentation).

Russo V, Ma Z, Deragon M, Dotson R, Catlett SV, Malik M. Characterization of oxi-dative stress regulator OxyR of Francisella tularensis. Eastern New York Student Chapter of the American Society for Microbiology (ENYSCASM), Albany, NY, November 4, 2015 (poster presentation).

Silver E, Szaro J, Dotson R, Catlett SV, Malik M. Char-acterization of a Francisella factor required for suppres-sion of innate immunity. Eastern New York Student Chapter of the American Society for Microbiology (ENYSCASM), Albany, NY, November 4, 2015 (poster presentation).

Ma Z, Russo V, Rabadi SM, Bakshi CS, Malik M. Regula-tion of Francisella tularensis genes involved in oxidative stress resistance. 115th Gen-eral Meeting of American So-ciety for Microbiology, New Orleans, LA, May 30 - June 2, 2015 (poster presentation).

Rabadi SM, Ma Z, Suresh RV, Catlett SV, Banik S, Ma-lik M, Bakshi CS. Antioxidant defenses of Francisella tularensis SchuS4 strain.

115th General Meeting of American Society for Microbiology, New Orleans, LA, May 30 - June 2, 2015 (poster presentation).

Ketkar H, Ma Z, Rabadi SM, Malik M, Bakshi CS. Char-acterization of the outer membrane component of the Emr-multidrug efflux pump. 115th General Meeting of American Society for Microbiology, New Orleans, LA, May 30 - June 2, 2015 (poster presentation).

Banik S, Mansour AM, Suresh RV, Malik M, Lee G, McCormick AA, Bakshi CS. Development of a multiva-lent subunit vaccine against tularemia using Tobacco Mosaic Virus (TMV) based delivery system. 115th Gener-al Meeting of American So-ciety for Microbiology, New Orleans, LA, May 30 - June 2, 2015 (poster presentation).

Wendy ParkerKaufman S, Parker WM, Campo-Engelstein L. Why are there so few male contraceptive options? A content analysis of con-temporary U.S. newspaper articles. Capital District Feminist Studies Confer-ence, Albany, NY, January 2015 (poster presentation).

Parker WM. Paradoxes to offer: The women’s health movement as a feminist project. Capital District Fem-inist Studies Conference, Albany, NY, January 2015 (oral presentation).

Parker WM, Burton-Chase AM. Provider satisfaction in colorectal cancer patients: A comparison between Lynch syndrome and sporadic survivors. Academy Health Annual Research Meeting, Minneapolis, MN, June 2015 (poster presentation).

Kaufman S, Parker WM, Campo-Engelstein L. Why are there so few male contraceptive options? A content analysis of con-temporary U.S. newspaper articles. Academy Health

Annual Research Meeting, Minneapolis, MN, June 2015 (poster presentation).

Parker WM, Ferreira K, Vernon L, Cardone KE. Medication management services in a dialysis center: Patient and staff perspec-tives. Academy Health Annual Research Meeting, Minneapolis, MN, June 2015 (poster presentation).

Parker WM, Donato KM, Burton-Chase AM. Preventive screenings and risks for women with Lynch syndrome: Initial results from a case-control study. Concordium Fall Research Conference, Washington, DC, September 2015 (poster presentation).

Parker WM, Jang SM, Pai AB, Cardone KE. Health literacy and quality in dial-ysis patients. Concordium Fall Research Conference, Washington, DC, September 2015 (poster presentation).

Parker WM, Donato KM, Burton-Chase AM. Preventive screening and risk for women with Lynch syndrome: Initial results of a case-control study. 19th Annual Meeting of the Collaborative Group of the Americas on Inherited Col-orectal Cancer (CGA-ICC), Baltimore, MD, October 2015 (poster presentation).

Wright D, Polimeni J, Meek P, Chandrasekara R, Parker WM. The impact of high deductible health plans on preventive care use. New York State Economics Association, Siena College, Albany, NY, October 2015 (oral presentation).

Parker WM, Smith RA. Peer social networks influence on health. New York State Economics Association, Siena College, Albany, NY, October 2015 (oral presen-tation).

Meek PD, Parker WM, Racz MJ, Cosler LE, Teynor ME. Differentiating oral

mesalamine adherence patterns in ulcerative colitis patients: A group-based trajectory model approach. Advances in Inflammatory Bowel Diseases: Crohn’s & Colitis Foundation’s Clinical and Research Conference, Orlando, FL, December 2015 (poster presentation).

Michael RaczRacz MJ, Sedransk J. Infer-ence for identifying outlying health care providers. 11th International Conference on Health Policy Statistics, Providence, RI, October 2015 (oral presentation).

Racz MJ. Inference for identifying outlying health care providers. UpStat 2015, Fourth Joint Conference of the Upstate ASA Chapters, Geneseo, NY, April 2015 (oral presentation).

Eric Yager Reid B, Visconti R, Harton JA, Yager EJ. Molecular reg-ulation of host inflammation during influenza A virus. Immunology 2015, Annual Meeting of the American Association of Immunolo-gists Annual Meeting, New Orleans, LA, May 8-12, 2015 (oral presentation).

GRANTS

Wendy Parker Investigators: Grabe D (PI), Parker WM (Co-PI), Daoui R (Co-PI)Project: Disparities in hyper-tension among women with chronic kidney diseaseGrantor: John Faunce and Alicia Tracy Roach FundAmount: $18,252 Term: July 1, 2015 - June 30, 2016

Parker WM (PI), Cardone KE (Co-PI), Daoui R (Co-PI). Project: Coping skills and self-management strategies used to increase medication adherence in the CKD populationGrantor: John Faunce and Alicia Tracy Roach FundAmount: $7,955Term: Sept 1, 2015 – August 31, 2016


D E P A R T M E N T O F H E A LT H S C I E N C E S

PUBLICATIONS

Binshan ShiHug K, Anthony L, Eldeiry D, Benson J, Wheeler E, Mousa SA, Shi B. Expression and tissue distribution of microRNA-21 in malignant and benign breast tissues. Anticancer Research, June 2015; 35(6): 3175-83.

Markus SteinMishra JP, Cohen D, Zamperone A, Nesic D, Muesch A, Stein M. CagA of helicobacter pylori interacts with and inhibits the serine- threonine kinase PRK2. Cell Microbiology, Nov 2015; 17(11): 1670-82.

Ebot TabePearson S, Kloos Z, Murray B, Tabe ES, Gupta M, Kwak JH, Karande P, McDonough K, Belfort G. Combined bioinformatic and rational design approach to develop antimicrobial peptides against mycobacterium tuberculosis. Antimicrobribal Agents and Chemotherapy,

Feb 2016, AAC.00940-15.

Tabe N, Rahman S, Tabe ES, Doetkott D, Khaitsa ML. Shigatoxin producing Esch-erichia coli and Salmonella spp burden in cattle feedlot runoff from two cattle feed-lot facilities in North Dakota. Food Protection Trends, Vol 36, No. 1, pp. 33-42.


Jenna BensonDiagnostic Seminar panel-ist. American Society for Cytopathology’s (ASC) Annual Scientific Conference, Chicago, IL, November 2015.

D E P A R T M E N T O F H U M A N I T I E S A N D C O M M U N I C A T I O N

PUBLICATIONS


Patricia BaiaBaia P, Strang A. Pharmacy educator motives to pursue pedagogical knowledge. American Journal of Pharma-ceutical Education, accepted October 2015 (in press).

Strang A, Baia P. An inves-tigation of teaching and learning programs in pharmacy education. American Journal of Phar-maceutical Education, Ref. AJPE5210R1, accepted June 2015 (in press).

Garrison G, Baia P, Canning J, Strang A. An asynchro-nous learning approach for the instructional component of a dual-campus pharmacy resident teaching program. American Journal of Pharmaceutical Education, v79 (2), 2015.

Paul DenvirDenvir P. Saving face during routine lifestyle history tak-ing: How patients report and remediate potentially prob-lematic conduct. Communi-cation & Medicine, accepted April 2015 (in press).

Margaret CarrollCarroll, Margaret Lasch. Ireland’s Great Famine in Irish-American History: Enshrining a Fateful Memo-ry by Mary C. Kelly (review). American Catholic Studies 126.1 (2015): 66-68.

REVIEW ARTICLES

Michael PittmanPittman M. Review of “The Holy Trinity and the Law of Three: Discovering the Radical Truth at the Heart of Christianity” by Cynthia Bourgeault. Journal for the Academic Study of Religions, 27.3, Feb 2015.


SCIENTIFIC POSTERS

Patricia BaiaBaia P. Faculty motivations for life-long learning. 45th Annual Conference of the International Society for Exploring Teaching and Learning, Savannah, GA, October 15-17, 2015.

Barry DeCosterDeCoster B. Medicalization versus demedicalization: The question of resistance. American Society for Bioethics and Humanities, Houston, TX, October 2015 (poster presentation)

INVITED PRESENTATIONS

Patricia BaiaBaia P, Strang A. Leverage: How to create an online certificate program using back-door tactics. Higher Educa-tion Pedagogy Conference, Virginia Tech, Blacksburg, VA, February 4-6, 2015.

Kevin HickeyHickey K. Infectious diaspo-ras: Africa and discourses of global health – bondage or

embrace? 41st Annual African Literature Association Con-ference – African Futures and Beyond: Visions in Tran-sition, University of Bayreuth, Germany, June 5, 2015.

Elisabeth VinesVines E. El Anatsui – Global Artist. 40th Annual NYASA Conference, Albany, NY, April 4, 2015.

PODIUM PRESENTATIONS

Barry DeCosterDeCoster B. Rethinking the ethics of expedited partner therapies. American Society for Bioethics and Humanities, Houston, TX, October 2015.

DeCoster B with Lisa Cam-po-Engelstein. The medical-ization of men’s reproduction. European Society for Philoso- phy of Medicine and Health- care. Paper included in special session on “The Biomed-ical Model and the Medical-ization of Healthcare,” Ghent, Belgium, August 2015.

DeCoster B. The Virtues of Uneasy Collaborations. North American Society for Social Philosophy, July 2015.

DeCoster B. Fishkin’s Bot-tlenecks: A Reply to Author. North American Society for Social Philosophy, July 2015.

DeCoster B. The Myth of Demedicalization? Annual Meeting of the Eastern So-ciological Society, New York, NY, Feb 26 - Mar 1, 2015.

Paul DenvirDenvir P. Discursive con-structions of Eric Garner and NYC police officers in the de Blasio/Bratton press conference. Presented at the 40th Annual Conference of New York Africana Stud-ies Conference, Albany Law School, April 2015. Michael PittmanPittman M. Reflections of orality and textualizations in Gurdjieff’s Beelzebub’s Tales to His Grandson. International Association for the History of Religions Conference, Erfurt, Germa-ny, August 23-29, 2015.

Pittman M. Desire and de-votion in Sergei Parajanov’s The Color of Pomegranates. American Academy of Reli-gion, Eastern International Region Conference, Montre-al, CA, May 1-2, 2015.

Pittman M. Responding to the crisis in higher educa-tion: A Taoist and contem-plative re-visioning of higher education and leadership. Comparative and Interna-tional Education Society Conference, Washington, DC, March 8-13, 2015.

Laura Rogers Rogers L. Re (claiming) Lila: Understanding the fragmentary narratives of in-carcerated girls in the early 20th century. Conference on College Composition and Communication, Tampa, FL, March 18-21, 2015.

Rogers L. Into the Archives. Narrative Truth: The Risks and Rewards of Prison Research, Writing and Teach-ing Workshop, Conference on College Composition and Communication, Tampa, FL, March 18-21, 2015.

Rogers L with Santicola T, Callaghan C, Kaley A, Yehia, A. We Don’t Talk About That Here: Or do we? (Dis) embodiment in the Science Based Writing Center. Northeast Writing Centers Association Confer-ence, Centenary College, Hackettstown, NJ, April 18-19 2015.

Rogers L with Jacobi T. Deviance or defiance: Counternarrating stories of incarcerated girls. 10th Annu-al Feminisms and Rhetorics Conference, Arizona State University, Tempe, AZ, October 28-31, 2015.

PROFESSIONAL APPOINTMENTS

Paul DenvirDenvir P. Vice-chair, Language and Social Inter-action Division of National Communication Associ-ation. Served as Division Planner for the 101st Annual Meetings, Las Vegas, NV, November 2015.

Kevin HickeyElected Vice President of The New York African Studies Association (2-year term) in April 2015.


P H A R M A C E U T I C A L R E S E A R C H I N S T I T U T E

PUBLICATIONS


Dhruba J. Bharali *Hariri W, Sudha T, Bharali DJ, Cui H, Mousa SA (2015). Nano-targeted delivery of toremifene, an estrogen receptor-alpha blocker in prostate cancer. Pharma-ceutical Research 32:2764-2774.

Safer AM, Hanafy NA, Bharali DJ, Cui H, Mousa SA (2015). Effect of green tea extract encapsulated into chitosan nanoparticles on hepatic fibrosis collagen fibers assessed by atomic force microscopy in rat hepatic fibrosis model. Journal of Nanoscience and Nanotechnology 15:6452-6459.

Shirode AB, Bharali DJ, Nallanthighal S, Coon JK, Mousa SA, Reliene R (2015). Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention. International Journal of Nanomedicine 10:475-484. Vandhana M-Chari *Alshaiban A, Muralidha-ran-Chari V, Nepo A, Mousa SA (2015). Modulation of sickle red blood cell adhesion and its associated changes in biomarkers by sulfated non-anticoagulant heparin derivative. Clinical and Applied Thrombosis/Hemostasis 22:230-238.

Paul J. Davis Davis PJ, Glinsky GV, Lin HY, Leith JT, Hercbergs A, Tang HY, Ashur-Fabian O, Incerpi S, Mousa SA (2015). Cancer cell gene expression mod-ulated from plasma mem-brane integrin alphavbeta3

by thyroid hormone and nanoparticulate tetrac. Frontiers in Endocrinology (Lausanne) 5:240.

Davis PJ, Incerpi S, Lin HY, Tang HY, Sudha T, Mousa SA (2015). Thyroid hormone and P-glycoprotein in tumor cells. BioMed Research International 2015:168427.

Hercbergs A, Johnson RE, Ashur-Fabian O, Garfield DH, Davis PJ (2015). Medi-cally induced euthyroid hy-pothyroxinemia may extend survival in compassionate need cancer patients: An observational study. The Oncologist 20:72-76.

Lin HY, Glinsky GV, Mousa SA, Davis PJ (2015). Thyroid hormone and anti-apoptosis in tumor cells. Oncotarget 6:14735-14743.

Shaker A. Mousa *Alshaiban A, Muralidha-ran-Chari V, Nepo A, Mousa SA (2015). Modulation of sickle red blood cell adhesion and its associated changes in biomarkers by sulfated non-anticoagulant heparin derivative. Clinical and Applied Thrombosis/Hemostasis 22:230-238.

*Al-Sofiani ME, Jammah A, Racz M, Khawaja RA, Hasanato R, El-Fawal HA, Mousa SA, Mason DL (2015). Effect of Vitamin D supplementation on glucose control and inflam-matory response in type ii diabetes: A double blind, randomized clinical trial. International Journal of Endocrinology and Metabo-lism 13:e22604.

*Alyahya R, Sudha T, Racz M, Stain SC, Mousa SA (2015). Anti-metastasis

efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. Interna-tional Journal of Oncology 46:1225-1231.

*Alzahri MS, Mousa SA, Almomen AM, Hasanato RM, Polimeni JM, Racz MJ (2015). Lactate dehydroge-nase as a biomarker for ear-ly renal damage in patients with sickle cell disease. Saudi Journal of Kidney Dis-eases and Transplantation 26:1161-1168.

Bani-Jaber A, Cui H, Elsaid A, Yalcin M, Sudha T, Mousa SA (2015). Pegylated solid lipid nanoparticles recon-stituted from high-density lipoprotein components for hepatic targeting. Science Letters Journal 4.

*Belousova V, Abd-Rabou AA, Mousa SA (2015). Recent advances and future directions in the management of hepatitis C infections. Pharmacology & Therapeutics 145:92-102.

Block RC, Abdolahi A, Tu X, Georas SN, Brenna JT, Phipps RP, Lawrence P, Mousa SA (2015). The effects of aspirin on platelet function and lysophos-phatidic acids depend on plasma concentrations of EPA and DHA. Pros-taglandins Leukotrienes and Essential Fatty Acids 96:17-24.

Darwish NHE, Mousa SA (2015). Extrinsic targeting strategies against acute my-eloid leukemic stem cells. Integrative Cancer Science and Therapeutics 2 DOI 10.15761/ICST.1000134.

Darwish NHE, Mousa SA (2015). Intrinsic targeting strategies against acute my-eloid leukemic stem cells. Integrative Cancer Science and Therapeutics 2. DOI: 10.15761/ICST.1000135.

Davis PJ, Glinsky GV, Lin HY, Leith JT, Hercbergs A, Tang HY, Ashur-Fabian O, Incerpi S, Mousa SA (2015). Cancer cell gene expression modulated from plasma membrane integrin alphavbeta3 by thyroid hormone and nanopartic-ulate tetrac. Frontiers in Endocrinology (Lausanne) 5:240.

Davis PJ, Incerpi S, Lin HY, Tang HY, Sudha T, Mousa SA (2015). Thyroid hormone and P-glycoprotein in tumor cells. BioMed Research International 2015:168427.

Davis PJ, Sudha T, Lin HY, Mousa SA (2015). Thyroid hormone, hormone ana-logs, and angiogenesis. Comprehensive Physiology 6:353-362.

*Ebright J, Mousa SA (2015). Oral anticoagulants and status of antidotes for the reversal of bleeding risk. Clinical and Applied Thrombosis-Hemostasis 21:105-114.

*Hariri W, Sudha T, Bharali DJ, Cui H, Mousa SA (2015). Nano-targeted delivery of toremifene, an estrogen receptor-alpha blocker in prostate cancer. Pharma-ceutical Research 32:2764-2774.

Hug KA, Anthony L, Eldeiry D, Benson J, Wheeler E, Mousa SA, Shi B (2015). Expression and tissue distribution of microrna-21

in malignant and benign breast tissues. Anticancer Research 35:3175-3183.

Lin HY, Glinsky GV, Mousa SA, Davis PJ (2015). Thyroid hormone and anti-apoptosis in tumor cells. Oncotarget 6:14735-14743.

Obradovic M, Zafirovic S, Jovanovic A, Milo-vanovic ES, Mousa SA, Labudovic-Borovic M, Isenovic ER (2015). Effects of 17 beta-estradiol on cardiac Na+/K+-ATPase in high fat diet fed rats. Molecular and Cellular Endocrinology 416:46-56.

Rajabi M, Hossaini Z, Khalilzadeh MA, Datta S, Halder M, Mousa SA (2015). Synthesis of a new class of furo 3, 2-c coumarins and its anticancer activity. Journal of Photochemistry and Photobiology B: Biology 148:66-72.

Safer AM, Afzal M, Hanafy N, Mousa SA (2015). Green tea extract therapy diminishes hepatic fibrosis mediated by dual exposure to carbon tetrachloride and ethanol: A histopatholog-ical study. Experimental and Therapeutic Medicine 9:787-794.

Safer AM, Sen A, Hanafy NA, Mousa SA (2015). Quantification of the healing effect in hepatic fi-brosis induced by chitosan nano-encapsulated green tea in rat model. Journal of Nanoscience and Nano-technology 15:9918-9924.

Safer AM, Hanafy NA, Bharali DJ, Cui H, Mousa SA (2015). Effect of green tea extract encapsulated into chitosan nanoparticles


I N S T R U C T I O N A L D E S I G N S E R V I C E S

on hepatic fibrosis collagen fibers assessed by atomic force microscopy in rat he-patic fibrosis model. Journal of Nanoscience and Nano-technology 15:6452-6459.

Shirode AB, Bharali DJ, Nallanthighal S, Coon JK, Mousa SA, Reliene R (2015). Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention. International Journal of Nanomedicine 10:475-484.

Srinivasan M, Rajabi M, Mousa SA (2015). Multi-functional nanomaterials and their applications in drug delivery and cancer therapy. Nanomaterials 5:1690-1703.

Stanimirovic J, Obradovic M, Zafirovic S, Resanovic I, Bogdanovic N, Gluvic Z, Mousa SA, Isenovic ER (2015). Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS. Clinical Lipidology 10:167-175.

Tarazi FI, Sahli ZT, *Pleskow J, Mousa SA (2015). Asperg-er’s syndrome: Diagnosis,

comorbidity and therapy. Expert Review of Neurother-apeutics 15:281-293.

Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, Cenic-Milosevic D, Jevremovic D, Ise-novic ER (2015). Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Critical Reviews in Clinical Laboratory Sciences 52:70-85.

*Vogel R, Hussein EA, Mousa SA (2015). Stem cells in the management of heart failure: What have we learned from clinical trials? Expert Review of Cardiovas-cular Therapy 13:75-83.

*Yasin BR, El-Fawal HA, Mou-sa SA (2015). Date (phoenix dactylifera) polypheno-lics and other bioactive compounds: A traditional Islamic remedy’s potential in prevention of cell damage, cancer therapeutics and beyond. International Jour-nal of Molecular Sciences 16:30075-30090.

BOOK CHAPTERS

El-Fawal HAN, *Rembisz R, *Alobaidi R, Mousa SA

(2016). “Chemotherapy-me-diated pain and periph-eral neuropathy: Impact of oxidative stress and inflammation” in Oxidative Stress and Antioxidant Protection. John Wiley & Sons, Inc, pp 367-388. DOI:10.1002/9781118832431.ch24.

* Denotes ACPHS Pharm.D. or M.S. students


Shaker A. MousaKeynote Speaker. 4th Hematology Congress XIII, Abu Dhabi, UE, Feb 2-6, 2015.

SUNY/Turkish Council Con-ference “Innovative Cancer Research - Translating Clinical and Population Research,” Albany, NY, April 15-17, 2015.

Keynote Speaker. Interna-tional Congress on Blood Disorders - Thalassemia / Sickle cell Diseases, May 4-8, 2015.

Keynote Speaker. Angio-genesis Symposium, Meet-

ing of the Physiological Society, Cardiff, Wales, July 5-8, 2015.

Best of Sciences presenta-tion. American Heart Associ-ation Meeting, Orlando, FL, November 7-11, 2015.

EXTRAMURAL GRANTS

Shaker A. MousaProject: Nanotetrac Synthesis Process Chem-istry for Production of Sterile Product: Evaluation of Physical/Chemical and Biological Profiles (Task 4)Grantor: Nano Pharmaceuticals LLCTotal award: $87,600 Start Date: 1/1/15

Project: Measurements of Diaminotetrac and Tetrac in Plasma Using LC/MS/MS (Task 4 Amendment)Grantor: Nano Pharmaceuticals LLCTotal award: $22,000 Start Date: 2/18/15

Project: Scale-Up of Nano Diaminotetrac for its Safety Assessment in Male and Female Mice after Daily Exposure at Different Doses

for 15 Days (Task 5).Grantor: Nano Pharmaceuticals LLCTotal award: $52,000 Start Date: 2/12/15

Project: Optimization of Nano-diamino-tetrac for-mulation for Scale up and assessment of Bioequiva-lence: Selection of Stabilizer (Task 3, Amendment A).Grantor: NanoPharmaceu-ticals LLCTotal award: $31,872 Start Date: 6/12/15

Project: Analytical Method Development for Nano-diamino-tetrac (N-DAT) Pharmacokinetic Studies (Task 6).Grantor: NanoPharmaceu-ticals LLCTotal award: $63,360 Start Date: 6/24/15

Project: Optimization of Nano-diamino-tetrac formulation (Highest Possible DAT % loading) for Scale up and assess-ment of Bioequivalence: Se-lection of Stabilizer (Task 7)Grantor: Nano Pharmaceuticals LLCTotal award: $74,958 Start Date: 10/28/15

PUBLICATIONS

Tammy Garren Zarbock S, Garren T. Graduated quizzes in a diabetes mellitus therapeutics module and impact on student learning and satisfaction. Currents in Pharmacy Teaching and Learning, 8, 39-46. DOI: http://dx.doi.org/10.1016/j.cptl.2015.09.019.

Garren T, Skylstad K. Scaffolded online learning modules for milliequiva-lency and milliosmolarity calculations. Currents in Pharmacy Teaching and Learning (in press).


Tammy GarrenGarren T, Skylstad K. Differentiated and flexible learning environ-ment for calculations in a pharmacy skills lab. Northeastern Educational Research Association Annual Conference, Trumbull, CT, October 2015 (poster session).

Marie Michaud-SacksKoo, CL, Farris C, Feinberg D, Michaud-Sacks M, Camiel LD, Goldman J. Flipped classroom in pharmacy education. American Association of Colleges of Pharmacy’s Technology in Pharmacy Education and Learning Special Interest Group (TiPEL SIG) webinar series, moderated by Demps, E, 2015.

Judy TengTeng J. Instructional design for everyone. NorthEast Re-gional Computing Program (NERCOMP), Affiliation of EDUCAUSE, Norwood, MA, November 2015 (invited panelist).


ASSETS Cash and cash equivalents ___________________ 24,596,188 Investments ______________________________ 45,022,987 Other assets ________________________________ 1,737,651 Accounts receivable - Students __________________ 450,230 Receivables-Government entities ________________ 405,697 Pledges receivable __________________________ 1,686,661 Student loan receivable ______________________ 2,510,358 Assets held in charitable remainder annuity trust ____ 164,780 Other receivables ____________________________ 268,270 Agency funds _______________________________ 331,563 Deposits with Bond Trustees ______________________10,251 Property, plant & equipment-Net ______________ 48,846,892

TOTAL ASSETS ______________________ $126,031,528

F I N A N C I A L R E P O R TJ U LY 1 , 2 0 1 4 – J U N E 3 0 , 2 0 1 5

LIABILITIES Accounts payable and accrued liabilities ________ $2,206,161 Deferred income and deposits ________________ $7,243,354 U.S. government grants refundable _____________ $2,313,459 Bonds payable ___________________________ $24,846,017 Expected post retirement benefit obligation ______ $1,791,640 Other liabilities _____________________________ $1,102,126 Deposits held in custody for others ______________ $331,563

TOTAL LIABILITIES ___________________$39,834,320

NET ASSETS Unrestricted net assets _____________________$73,578,075 Temporarily restricted assets_________________ $4,396,059 Permanently restricted assets ________________ $8,223,074

TOTAL NET ASSETS ___________________ $86,197,208 TOTAL LIABILITIES AND NET ASSETS ___ $126,031,528

NET ASSETS

TOTAL ASSETS

REVENUES Student tuition and fees _________________________ 74.15% Auxiliary enterprises ____________________________9.20% Gifts and pledges ______________________________4.99% Government contracts and grants __________________ 4.77% Other sources _________________________________3.53% Investment income _____________________________3.22% Postgraduate education _________________________ 0.14%

TOTAL ______________________________________ 100%

STATEMENT OF FINANCIAL POSITION

STATEMENT OF ACTIVITIES

EXPENSES Instruction/Student services ______________________ 43.77% Physical plant ________________________________ 26.51% General administration __________________________18.12% Research _____________________________________6.29% Institutional advancement ________________________3.03% Student financial aid ____________________________ 1.67% Postgraduate education _________________________ 0.61%

TOTAL ______________________________________ 100%

TOTAL LIABILITIES

REVENUES

EXPENSES


BOARD OF TRUSTEESOFFICERSHerbert Chorbajian, ChairmanMarion Morton, ’84, Vice ChairChristopher D. Mitiguy, TreasurerKandyce J. Daley, ’74, Secretary

TERM TRUSTEESStephen AinlayMatthew BetteRaymond Bleser Jr., ’81Walter S. BorisenokLeigh Briscoe-Dwyer, ’87Thomas D’AmbraPaul DerOhannesian IIChris Di Lascia, ’83Michael Duteau, ’92Geno J. Germano, ’83Rocco Giruzzi, ’58Susan Learned, ’91James Notaro, ’84Scott Terrillion, ’85Pamela Williamson

PUBLISHED MAY 2016

EDITOR Gil Chorbajian

PHOTOGRAPHYBrad ParisKris QuaShayne Ross

DESIGN2Communiqué

106 NEW SCOTLAND AVENUEALBANY, NY 12208WWW.ACPHS.EDU

A L B A N Y C O L L E G E O F P H A R M A C Y A N D H E A LT H S C I E N C E S

Documents

ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES